U.S. patent number 9,790,550 [Application Number 12/992,965] was granted by the patent office on 2017-10-17 for asthma susceptibility loci located at chromosome 1q31 for use in diagnostic and therapeutic methods.
This patent grant is currently assigned to The Children's Hospital of Philadelphia. The grantee listed for this patent is Hakon Hakonarson, Patrick M. A. Sleiman. Invention is credited to Hakon Hakonarson, Patrick M. A. Sleiman.
United States Patent |
9,790,550 |
Hakonarson , et al. |
October 17, 2017 |
Asthma susceptibility loci located at chromosome 1q31 for use in
diagnostic and therapeutic methods
Abstract
Methods and composition are provided for diagnosing pediat.pi.c
onset asthma based on the single nucleotide polymorphism on
chromosome 1q31 wherein said single nucleotide polymorphism is set
forth in Table 2 or Table 6 of the instant invention Method and
composition are also provided for treating and preventing asthma or
other inflammatory conditions in a patient in need thereof
comp.pi.sing administering an effective amount of an at least one
inhibitor which reduces the expression of DENND1 B gene
product.
Inventors: |
Hakonarson; Hakon (Malvern,
PA), Sleiman; Patrick M. A. (Philadelphia, PA) |
Applicant: |
Name |
City |
State |
Country |
Type |
Hakonarson; Hakon
Sleiman; Patrick M. A. |
Malvern
Philadelphia |
PA
PA |
US
US |
|
|
Assignee: |
The Children's Hospital of
Philadelphia (Philadelphia, PA)
|
Family
ID: |
41319389 |
Appl.
No.: |
12/992,965 |
Filed: |
May 18, 2009 |
PCT
Filed: |
May 18, 2009 |
PCT No.: |
PCT/US2009/044412 |
371(c)(1),(2),(4) Date: |
April 29, 2011 |
PCT
Pub. No.: |
WO2009/140699 |
PCT
Pub. Date: |
November 19, 2009 |
Prior Publication Data
|
|
|
|
Document
Identifier |
Publication Date |
|
US 20110200583 A1 |
Aug 18, 2011 |
|
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
61053808 |
May 16, 2008 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P
11/06 (20180101); C12Q 1/6883 (20130101); C12Q
2600/156 (20130101); C12Q 2600/158 (20130101); C12Q
2600/136 (20130101) |
Current International
Class: |
C07H
21/02 (20060101); C12Q 1/68 (20060101); C07H
21/04 (20060101); C12P 19/34 (20060101) |
References Cited
[Referenced By]
U.S. Patent Documents
Other References
dbSNP Submitted SNP(ss) Details: ss70751518, rs2786098 (Apr. 20,
2007), from www.ncbi.nlm.nih.gov, p. 1. cited by examiner .
GenBank Locus BC063877 `Homo sapiens DENN/MADD domain containing
1B, mRNA` (Sep. 9, 2005) from www.ncbi.nlm.nih.gov, pp. 1-4. cited
by examiner .
Gunderson K.L. et al. Pharmacogenomics Jun. 2006, vol. 7, No. 4,
pp. 641-648. cited by examiner .
Reference SNP(refSNP) Cluster Report: rs2821132, from
www.ncbi.nlm.nih.gov, pp. 1-3, printed Jul. 22, 2013. cited by
examiner .
Reference SNP(refSNP) Cluster Report: rs2476019, from
www.ncbi.nlm.nih.gov, pp. 1-3, printed Jul. 22, 2013. cited by
examiner .
Reference SNP(refSNP) Cluster Report: rs2759661, from
www.ncbi.nlm.nih.gov, pp. 1-3, printed Jul. 22, 2013. cited by
examiner .
Larin Z. et al. Nucleic Acids Research, 1994, vol. 22, No. 18, pp.
3689-3692. cited by examiner .
Anderson R.C. et al. "Polynucleotide Arrays for Genetic Sequence
Analysis" in Topics in Current Chemistry,vol. 194 (1998), pp.
117-129. cited by examiner .
Macewan, D.J. "TNF ligands and receptors--a matter of life and
death." Br J Pharmacol. Feb. 2002;135(4):855-75. cited by applicant
.
NCBI Entrez Single Nucleotide Polymorphism entry rs2477077
[Retrieved from the Internet on Sep. 15, 2009:
<http://www.ncbi.mln/nih.gov/SNP/snp.sub.--ref.cgi?searchType=adhoc.su-
b.--search&type=rs&rs=rs2477077> May 25, 2006 (May 25,
2006); p. 1. cited by applicant.
|
Primary Examiner: Kapushoc; Stephen
Attorney, Agent or Firm: Rigaut; Kathleen D. Dann, Dorfman,
Herrell & Skillman
Parent Case Text
This application is a .sctn.371 national phase entry of
PCT/US2009/044412 filed May 18, 2009, which claims priority to U.S.
Provisional Application 61/053,808 filed May 16, 2008, the entire
contents of which is incorporated herein by reference.
Claims
What is claimed is:
1. A solid support having affixed thereon a collection of single
nucleotide polymorphism (SNP)-containing isolated nucleic acids
wherein each nucleic acid of the collection is at least 15
nucleotides in length, wherein the collection includes each allele
of the SNPs, said SNPs being associated with an altered risk of
developing pediatric onset asthma and consisting of rs2786098,
rs2821106, rs12134409, rs2111931, rs10737692, rs12127378,
rs12041661, rs10442656, rs2477070, rs1747827, rs2488411, rs1891497,
rs1747815, rs1775454, rs1775456, rs1924518, rs1775444, rs12026183,
rs10922300, rs10922326, rs2821125, rs1337168, rs1337167, rs2786101,
rs2821116, rs2786119rs2786117, rs10801603, rs2821107, rs2759656,
rs2821103, rs2759661, rs2476019, rs2821132, rs17554990, rs6685222,
rs17555558, rs10922234, rs12023045, rs12563307,
rs12133659rs12132165, rs4915550, rs4915551, rs4915552, rs10754224,
rs4316386, rs10922251, rs6677361, rs12028758, rs10922253,
rs10494758, rs2111931, rs1421397, rs6689216, rs10922255,
rs10922256, rs10922257, rs6676073, rs10737692, rs4915555,
rs12131160, rs2193734, rs8179369, rs12747786, rs6428411, rs6428412,
rs1833464, rs1362939, rs12116508, rs4915557, rs4915558, rs3814321,
rs12133885, rs1775453, rs2488409, rs2488410, rs1775450, rs1747811,
rs1578720, rs2358774, rs1573098, rs1621898, rs1775457, rs2147300,
rs2488387, rs1747815, rs1747814, rs2488400, rs1747817, rs1775441,
rs1775442, rs1342696, rs1539413, rs2488394, rs2488395, rs2488396,
rs1342694, rs2477069, rs1775469, rs1747825, rs1775468, rs1775467,
rs1775466, rs1775465, rs1775464, rs1747823, rs2454640, rs1499593,
rs10922288, rs12740849, rs2133536, rs12125742, rs4915566,
rs6428417, rs10922294, rs6697696, rs6704186, rs4915569, rs12140293,
rs12118454, rs10801625, rs10922304, rs10922305, rs1499602,
rs10801629, rs10801632, and rs9662705, wherein said isolated
SNP-containing nucleic acids are immobilized on a gene chip or a
solid support.
2. The isolated collection of nucleic acids as claimed in claim 1,
wherein said solid support is a microarray and is present in a
kit.
3. The kit of claim 2, comprising said microarray, a sample
container, and reagents for analyzing a polynucleotide sample
obtained from a subject, wherein the nucleic acids of the
collection are probes between 15-25 nucleotides in length.
Description
FIELD OF THE INVENTION
This invention relates to the fields of airway disease and genetic
testing. More specifically, the invention provides compositions and
methods for the diagnosis and treatment of asthma and other
allergic conditions.
BACKGROUND OF THE INVENTION
Several publications and patent documents are cited throughout the
specification in order to describe the state of the art to which
this invention pertains. Each of these citations is incorporated by
reference herein as though set forth in full.
Asthma is a heterogeneous and multifactorial disease that manifests
as episodes of wheezing, coughing and shortness of breath. Both
family-based and twin studies indicate that asthma is a complex
genetic disorder.sup.1. Multiple genetic and environmental factors
are also known to modulate the clinical expression of the disease
and its associated phenotypes, bronchial hyper-responsiveness,
atopy, and elevated IgE.sup.2,.sup.3. In a recent GWA study, a
single locus harboring ORMDL3 on 17q12-q21 was found to associate
with asthma contributing modestly to disease risk, thereby notably
reducing the possibility of the presence of common variants with
large effect size in asthma.sup.6. However, as only a small
proportion of the disease heritability has been explained to date,
it follows that additional high frequency variants of modest risk
remain to be uncovered. The identification of further genetic
predisposition loci may lead to improved understanding of the
biological basis of the disease and potentially also serve as new
therapeutic targets.
GWA has proven to be a robust approach to gene variant discovery in
complex disease.sup.7. However, unlike type 2 diabetes or
inflammatory bowel disease (IBD) where multiple variants underlying
the genetic susceptibility to these conditions have been
discovered.sup.8,9, only a single locus has thus far been shown to
associate with asthma predisposition through GWA.sup.6. This
suggests that either substantially larger numbers of subjects need
to be studied, as with type 2 diabetes and IBD, or the sample must
be enriched for genetic disease by sampling for lower age of onset
or increased disease severity. Age of onset is one of the most
easily tractable asthma phenotypes and, as longitudinal studies
have established, strongly correlated with a number of other asthma
phenotypes.sup.4,5.
Clearly a need exists to identify other genes involved in the
manifestation of the asthmatic phenotype, particularly pediatric
onset asthma. Such knowledge will facilitate diagnosis of this
condition as well as provide new targets for the development of
potent therapeutics for the treatment of asthma.
SUMMARY OF THE INVENTION
In accordance with the present invention, compositions and methods
are provided for diagnosis and treatment of asthma. An exemplary
method entails detecting the presence of at least one genetic
alteration, e.g., a single nucleotide polymorphism, on chromosome
1q31 in a target polynucleotide wherein if the single nucleotide
polymorphism is present, the patient has an increased risk for
developing asthma. Exemplary single nucleotide polymorphisms
associated with the development of asthma include, without
limitation, those disclosed in the Tables hereinbelow. Such
pediatric onset associated genetic alterations may also be detected
in the linkage disequilibrium block present between positions
193434182 (rs 2284664) and 195052641 on chromosome 1.
The methods of the invention can include alternative means for
detecting the disclosed genetic alterations and polymorphisms. For
example, such methods of detection can further comprises processes
such as specific hybridization, measurement of allele size,
restriction fragment length polymorphism analysis, allele-specific
hybridization analysis, single base primer extension reaction, and
sequencing of an amplified polynucleotide.
In a preferred embodiment, the polymorphism is on chromosome 1q31
and is provided in Tables 2 and 6.
In yet another aspect, nucleic acid molecules useful for amplifying
the nucleic acids encoding the single nucleotide polymorphisms
disclosed herein are provided. Also provided are solid supports
comprising suitable nucleic acid targets to facilitate detection of
such SNPS in patient samples. A suitable solid support for this
process includes a microarray.
Finally, the invention also encompasses screening methods to
identify agents which modulate the aberrant IgE production,
brochoconstriction and airway inflammation observed in the
asthma-associated SNP containing cells described herein. An
exemplary method entails providing cells comprising at least one of
the SNPs disclosed in Table 1; providing cells which express these
gene(s) which lack the cognate polymorphisms (step b); contacting
each cell type with a test agent and analyzing whether said agent
alters parameters associated with the asthmatic phenotype. Agents
so identified are also within the scope of the invention. Exemplary
agents for down-modulating the expression of the DENND1B gene
include siRNA molecules which are provided below in Table 13. Such
siRNA should have efficacy for the treatment of asthma and may be
used alone or in combination with agents conventionally used to
treat this disease.
Also provided are transgenic mice comprising the SNP containing
nucleic acid molecules described herein. Such mice provide a
superior in vivo screening tool to identify agents which modulate
the progression and development of asthma.
BRIEF DESCRIPTION OF THE DRAWING
FIG. 1: Representation of the chromosome 1q31 associated interval.
Panel A: Scatter plot of the log.sub.10 P values plotted by base
pair. Common coordinates for the X-axis are given at the bottom of
the figure. Panel B: Recombination rate around the associated
interval. Dashed black lines across panels A and B represent
demarcation of the associated interval where p-values and odds
ratios return to background levels. Panel C: Location of the CRB1
and DENND1B genes and the associated SNPs in relation to these
genes, all SNPs were intergenic or intronic. Panel D: LD plot of
the r.sup.2 values in CHOP AA control samples. Panel E: LD plot of
the r.sup.2 values in the CHOP EA control samples.
FIG. 2: Manhattan Plot of the combined European ancestry asthma
cases. Log10 P-values are plotted against physical distance. Two
loci at chromosome 1q31 and 17q21 were significantly associated
with asthma following Bonferroni correction.
FIG. 3: D' and r.sup.2 LD plots of the CHOP discovery EA and AA
control samples. The numbered SNPs 1-20 correspond to the
associated SNPs listed in table 2.
FIG. 4: Median DENND1B expression across all tissues. The purple
lines correspond to 3 times the median value (3.times.M) and 10
times the median (10.times.M). Dendritic cells and Natural Killer
cells (light blue columns) express DENND1B over 10 times the median
value.
FIG. 5: Cells possessing different DENND1B alleles exhibit
differential induced cytokine production in NK cell lines
DETAILED DESCRIPTION OF THE INVENTION
Asthma is a complex disease with both genetic and environmental
components. However, the genetic susceptibility factors
underpinning what is the most common chronic childhood disease
remain largely unknown. We have carried out a whole genome
association study genotyping over 545,000 SNPs in 569 North
American asthmatics of European ancestry and 2136 disease-free
controls. We describe a locus on chromosome 1q31 containing
multiple common variants that are highly and reproducibly
associated with pediatric onset asthma (p<10.sup.-8). Upon
replication, the chromosome 1q31 locus showed significant
association with asthma in two independent cohorts comprising 2011
Northern European subjects (p<10.sup.-7) and 3429 African
American children (p<10.sup.-4), respectively. Further analysis
of the associated interval indicated that all the associated SNPs
mapped to a block of high linkage disequilibrium (LD) that spanned
the DENND1B gene and the 3' end of the CRB1 gene. DENND1B, a
dendritic cell expressed protein, is a member of the DENN/MADD
domain containing proteins that are known to interact with the
TNF.alpha. receptor, a well established asthma pathway
candidate.
In accordance with the present invention, high density SNP-based
genotyping technology has been applied in GWA studies which have
resulted in the identification of genes and genetic variants that
contribute to asthma in well-defined pediatric study populations.
This discovery impacts on millions of children in the US and the
rest of the world with asthma.
Definitions:
For purposes of the present invention, "a" or "an" entity refers to
one or more of that entity; for example, "a cDNA" refers to one or
more cDNA or at least one cDNA. As such, the terms "a" or "an,"
"one or more" and "at least one" can be used interchangeably
herein. It is also noted that the terms "comprising," "including,"
and "having" can be used interchangeably. Furthermore, a compound
"selected from the group consisting of" refers to one or more of
the compounds in the list that follows, including mixtures (i.e.
combinations) of two or more of the compounds. According to the
present invention, an isolated, or biologically pure molecule is a
compound that has been removed from its natural milieu. As such,
"isolated" and "biologically pure" do not necessarily reflect the
extent to which the compound has been purified. An isolated
compound of the present invention can be obtained from its natural
source, can be produced using laboratory synthetic techniques or
can be produced by any such chemical synthetic route.
"Asthma-associated SNP or specific marker" is a SNP or marker which
is associated with an increased or decreased risk of developing
asthma not found normal patients who do not have this disease. Such
markers may include but are not limited to nucleic acids, proteins
encoded thereby, or other small molecules.
A "single nucleotide polymorphism (SNP)" refers to a change in
which a single base in the DNA differs from the usual base at that
position. These single base changes are called SNPs or "snips."
Millions of SNP's have been cataloged in the human genome. Some
SNPs such as that which causes sickle cell are responsible for
disease. Other SNPs are normal variations in the genome.
The term "genetic alteration" as used herein refers to a change
from the wild-type or reference sequence of one or more nucleic
acid molecules. Genetic alterations include without limitation,
base pair substitutions, additions and deletions of at least one
nucleotide from a nucleic acid molecule of known sequence.
"Linkage" describes the tendency of genes, alleles, loci or genetic
markers to be inherited together as a result of their location on
the same chromosome, and is measured by percent recombination (also
called recombination fraction, or .theta.) between the two genes,
alleles, loci or genetic markers. The closer two loci physically
are on the chromosome, the lower the recombination fraction will
be. Normally, when a polymorphic site from within a disease-causing
gene is tested for linkage with the disease, the recombination
fraction will be zero, indicating that the disease and the
disease-causing gene are always co-inherited. In rare cases, when a
gene spans a very large segment of the genome, it may be possible
to observe recombination between polymorphic sites on one end of
the gene and causative mutations on the other. However, if the
causative mutation is the polymorphism being tested for linkage
with the disease, no recombination will be observed.
"Centimorgan" is a unit of genetic distance signifying linkage
between two genetic markers, alleles, genes or loci, corresponding
to a probability of recombination between the two markers or loci
of 1% for any meiotic event.
"Linkage disequilibrium" or "allelic association" means the
preferential association of a particular allele, locus, gene or
genetic marker with a specific allele, locus, gene or genetic
marker at a nearby chromosomal location more frequently than
expected by chance for any particular allele frequency in the
population.
The term "solid matrix" as used herein refers to any format, such
as beads, microparticles, a microarray, the surface of a
microtitration well or a test tube, a dipstick or a filter. The
material of the matrix may be polystyrene, cellulose, latex,
nitrocellulose, nylon, polyacrylamide, dextran or agarose.
The phrase "consisting essentially of" when referring to a
particular nucleotide or amino acid means a sequence having the
properties of a given SEQ ID NO:. For example, when used in
reference to an amino acid sequence, the phrase includes the
sequence per se and molecular modifications that would not affect
the functional and novel characteristics of the sequence.
"Target nucleic acid" as used herein refers to a previously defined
region of a nucleic acid present in a complex nucleic acid mixture
wherein the defined wild-type region contains at least one known
nucleotide variation which may or may not be associated with
asthma. The nucleic acid molecule may be isolated from a natural
source by cDNA cloning or subtractive hybridization or synthesized
manually. The nucleic acid molecule may be synthesized manually by
the triester synthetic method or by using an automated DNA
synthesizer.
With regard to nucleic acids used in the invention, the term
"isolated nucleic acid" is sometimes employed. This term, when
applied to DNA, refers to a DNA molecule that is separated from
sequences with which it is immediately contiguous (in the 5' and 3'
directions) in the naturally occurring genome of the organism from
which it was derived. For example, the "isolated nucleic acid" may
comprise a DNA molecule inserted into a vector, such as a plasmid
or virus vector, or integrated into the genomic DNA of a prokaryote
or eukaryote. An "isolated nucleic acid molecule" may also comprise
a cDNA molecule. An isolated nucleic acid molecule inserted into a
vector is also sometimes referred to herein as a recombinant
nucleic acid molecule.
With respect to RNA molecules, the term "isolated nucleic acid"
primarily refers to an RNA molecule encoded by an isolated DNA
molecule as defined above. Alternatively, the term may refer to an
RNA molecule that has been sufficiently separated from RNA
molecules with which it would be associated in its natural state
(i.e., in cells or tissues), such that it exists in a
"substantially pure" form.
By the use of the term "enriched" in reference to nucleic acid it
is meant that the specific DNA or RNA sequence constitutes a
significantly higher fraction (2-5 fold) of the total DNA or RNA
present in the cells or solution of interest than in normal cells
or in the cells from which the sequence was taken. This could be
caused by a person by preferential reduction in the amount of other
DNA or RNA present, or by a preferential increase in the amount of
the specific DNA or RNA sequence, or by a combination of the two.
However, it should be noted that "enriched" does not imply that
there are no other DNA or RNA sequences present, just that the
relative amount of the sequence of interest has been significantly
increased.
It is also advantageous for some purposes that a nucleotide
sequence be in purified form. The term "purified" in reference to
nucleic acid does not require absolute purity (such as a
homogeneous preparation); instead, it represents an indication that
the sequence is relatively purer than in the natural environment
(compared to the natural level, this level should be at least 2-5
fold greater, e.g., in terms of mg/ml). Individual clones isolated
from a cDNA library may be purified to electrophoretic homogeneity.
The claimed DNA molecules obtained from these clones can be
obtained directly from total DNA or from total RNA. The cDNA clones
are not naturally occurring, but rather are preferably obtained via
manipulation of a partially purified naturally occurring substance
(messenger RNA). The construction of a cDNA library from mRNA
involves the creation of a synthetic substance (cDNA) and pure
individual cDNA clones can be isolated from the synthetic library
by clonal selection of the cells carrying the cDNA library. Thus,
the process which includes the construction of a cDNA library from
mRNA and isolation of distinct cDNA clones yields an approximately
10.sup.-6-fold purification of the native message. Thus,
purification of at least one order of magnitude, preferably two or
three orders, and more preferably four or five orders of magnitude
is expressly contemplated. Thus the term "substantially pure"
refers to a preparation comprising at least 50-60% by weight the
compound of interest (e.g., nucleic acid, oligonucleotide, etc.).
More preferably, the preparation comprises at least 75% by weight,
and most preferably 90-99% by weight, the compound of interest.
Purity is measured by methods appropriate for the compound of
interest.
The term "complementary" describes two nucleotides that can form
multiple favorable interactions with one another. For example,
adenine is complementary to thymine as they can form two hydrogen
bonds. Similarly, guanine and cytosine are complementary since they
can form three hydrogen bonds. Thus if a nucleic acid sequence
contains the following sequence of bases, thymine, adenine, guanine
and cytosine, a "complement" of this nucleic acid molecule would be
a molecule containing adenine in the place of thymine, thymine in
the place of adenine, cytosine in the place of guanine, and guanine
in the place of cytosine. Because the complement can contain a
nucleic acid sequence that forms optimal interactions with the
parent nucleic acid molecule, such a complement can bind with high
affinity to its parent molecule.
With respect to single stranded nucleic acids, particularly
oligonucleotides, the term "specifically hybridizing" refers to the
association between two single-stranded nucleotide molecules of
sufficiently complementary sequence to permit such hybridization
under pre-determined conditions generally used in the art
(sometimes termed "substantially complementary"). In particular,
the term refers to hybridization of an oligonucleotide with a
substantially complementary sequence contained within a
single-stranded DNA or RNA molecule of the invention, to the
substantial exclusion of hybridization of the oligonucleotide with
single-stranded nucleic acids of non-complementary sequence. For
example, specific hybridization can refer to a sequence which
hybridizes to any asthma specific marker nucleic acid, but does not
hybridize to other nucleotides. Also polynucleotide which
"specifically hybridizes" may hybridize only to an airway specific
marker, such as an asthma-specific marker shown in the Tables
contained herein. Appropriate conditions enabling specific
hybridization of single stranded nucleic acid molecules of varying
complementarity are well known in the art.
For instance, one common formula for calculating the stringency
conditions required to achieve hybridization between nucleic acid
molecules of a specified sequence homology is set forth below
(Sambrook et al., Molecular Cloning, Cold Spring Harbor Laboratory
(1989): T.sub.m=81.5.degree. C.+16.6 Log[Na+]+0.41(% G+C)-0.63 (%
formamide)-600/#bp in duplex
As an illustration of the above formula, using [Na+]=[0.368] and
50% formamide, with GC content of 42% and an average probe size of
200 bases, the T.sub.m is 57.degree. C. The T.sub.m of a DNA duplex
decreases by 1-1.5.degree. C. with every 1% decrease in homology.
Thus, targets with greater than about 75% sequence identity would
be observed using a hybridization temperature of 42.degree. C.
The stringency of the hybridization and wash depend primarily on
the salt concentration and temperature of the solutions. In
general, to maximize the rate of annealing of the probe with its
target, the hybridization is usually carried out at salt and
temperature conditions that are 20-25.degree. C. below the
calculated T.sub.m of the hybrid. Wash conditions should be as
stringent as possible for the degree of identity of the probe for
the target. In general, wash conditions are selected to be
approximately 12-20.degree. C. below the T.sub.m of the hybrid. In
regards to the nucleic acids of the current invention, a moderate
stringency hybridization is defined as hybridization in
6.times.SSC, 5.times. Denhardt's solution, 0.5% SDS and 100
.mu.g/ml denatured salmon sperm DNA at 42.degree. C., and washed in
2.times.SSC and 0.5% SDS at 55.degree. C. for 15 minutes. A high
stringency hybridization is defined as hybridization in
6.times.SSC, 5.times. Denhardt's solution, 0.5% SDS and 100
.mu.g/ml denatured salmon sperm DNA at 42.degree. C., and washed in
1.times.SSC and 0.5% SDS at 65.degree. C. for 15 minutes. A very
high stringency hybridization is defined as hybridization in
6.times.SSC, 5.times. Denhardt's solution, 0.5% SDS and 100
.mu.g/ml denatured salmon sperm DNA at 42.degree. C., and washed in
0.1.times.SSC and 0.5% SDS at 65.degree. C. for 15 minutes.
The term "oligonucleotide," as used herein is defined as a nucleic
acid molecule comprised of two or more ribo- or
deoxyribonucleotides, preferably more than three. The exact size of
the oligonucleotide will depend on various factors and on the
particular application and use of the oligonucleotide.
Oligonucleotides, which include probes and primers, can be any
length from 3 nucleotides to the full length of the nucleic acid
molecule, and explicitly include every possible number of
contiguous nucleic acids from 3 through the full length of the
polynucleotide. Preferably, oligonucleotides are at least about 10
nucleotides in length, more preferably at least 15 nucleotides in
length, more preferably at least about 20 nucleotides in
length.
The term "probe" as used herein refers to an oligonucleotide,
polynucleotide or nucleic acid, either RNA or DNA, whether
occurring naturally as in a purified restriction enzyme digest or
produced synthetically, which is capable of annealing with or
specifically hybridizing to a nucleic acid with sequences
complementary to the probe. A probe may be either single-stranded
or double-stranded. The exact length of the probe will depend upon
many factors, including temperature, source of probe and use of the
method. For example, for diagnostic applications, depending on the
complexity of the target sequence, the oligonucleotide probe
typically contains 15-25 or more nucleotides, although it may
contain fewer nucleotides. The probes herein are selected to be
complementary to different strands of a particular target nucleic
acid sequence. This means that the probes must be sufficiently
complementary so as to be able to "specifically hybridize" or
anneal with their respective target strands under a set of
pre-determined conditions. Therefore, the probe sequence need not
reflect the exact complementary sequence of the target. For
example, a non-complementary nucleotide fragment may be attached to
the 5' or 3' end of the probe, with the remainder of the probe
sequence being complementary to the target strand. Alternatively,
non-complementary bases or longer sequences can be interspersed
into the probe, provided that the probe sequence has sufficient
complementarity with the sequence of the target nucleic acid to
anneal therewith specifically.
The term "primer" as used herein refers to an oligonucleotide,
either RNA or DNA, either single-stranded or double-stranded,
either derived from a biological system, generated by restriction
enzyme digestion, or produced synthetically which, when placed in
the proper environment, is able to functionally act as an initiator
of template-dependent nucleic acid synthesis. When presented with
an appropriate nucleic acid template, suitable nucleoside
triphosphate precursors of nucleic acids, a polymerase enzyme,
suitable cofactors and conditions such as a suitable temperature
and pH, the primer may be extended at its 3' terminus by the
addition of nucleotides by the action of a polymerase or similar
activity to yield a primer extension product. The primer may vary
in length depending on the particular conditions and requirement of
the application. For example, in diagnostic applications, the
oligonucleotide primer is typically 15-25 or more nucleotides in
length. The primer must be of sufficient complementarity to the
desired template to prime the synthesis of the desired extension
product, that is, to be able anneal with the desired template
strand in a manner sufficient to provide the 3' hydroxyl moiety of
the primer in appropriate juxtaposition for use in the initiation
of synthesis by a polymerase or similar enzyme. It is not required
that the primer sequence represent an exact complement of the
desired template. For example, a non-complementary nucleotide
sequence may be attached to the 5' end of an otherwise
complementary primer. Alternatively, non-complementary bases may be
interspersed within the oligonucleotide primer sequence, provided
that the primer sequence has sufficient complementarity with the
sequence of the desired template strand to functionally provide a
template-primer complex for the synthesis of the extension
product.
Polymerase chain reaction (PCR) has been described in U.S. Pat.
Nos. 4,683,195, 4,800,195, and 4,965,188, the entire disclosures of
which are incorporated by reference herein.
An "siRNA" refers to a molecule involved in the RNA interference
process for a sequence-specific post-transcriptional gene silencing
or gene knockdown by providing small interfering RNAs (siRNAs) that
has homology with the sequence of the targeted gene. Small
interfering RNAs (siRNAs) can be synthesized in vitro or generated
by ribonuclease III cleavage from longer dsRNA and are the
mediators of sequence-specific mRNA degradation. Preferably, the
siRNA of the invention are chemically synthesized using
appropriately protected ribonucleoside phosphoramidites and a
conventional DNA/RNA synthesizer. The siRNA can be synthesized as
two separate, complementary RNA molecules, or as a single RNA
molecule with two complementary regions. Commercial suppliers of
synthetic RNA molecules or synthesis reagents include Applied
Biosystems (Foster City, Calif., USA), Proligo (Hamburg, Germany),
Dharmacon Research (Lafayette, Colo., USA), Pierce Chemical (part
of Perbio Science, Rockford, Ill., USA), Glen Research (Sterling,
Va., USA), ChemGenes (Ashland, Mass., USA) and Cruachem (Glasgow,
UK). Specific siRNA constructs for inhibiting DENN/D1B mRNA, for
example, may be between 15-35 nucleotides in length, and more
typically about 21 nucleotides in length. Exemplary siRNA sequences
effective for down-modulating expression of the DENND1B are
provided in Table 13.
The term "vector" relates to a single or double stranded circular
nucleic acid molecule that can be infected, transfected or
transformed into cells and replicate independently or within the
host cell genome. A circular double stranded nucleic acid molecule
can be cut and thereby linearized upon treatment with restriction
enzymes. An assortment of vectors, restriction enzymes, and the
knowledge of the nucleotide sequences that are targeted by
restriction enzymes are readily available to those skilled in the
art, and include any replicon, such as a plasmid, cosmid, bacmid,
phage or virus, to which another genetic sequence or element
(either DNA or RNA) may be attached so as to bring about the
replication of the attached sequence or element. A nucleic acid
molecule of the invention can be inserted into a vector by cutting
the vector with restriction enzymes and ligating the two pieces
together.
Many techniques are available to those skilled in the art to
facilitate transformation, transfection, or transduction of the
expression construct into a prokaryotic or eukaryotic organism. The
terms "transformation", "transfection", and "transduction" refer to
methods of inserting a nucleic acid and/or expression construct
into a cell or host organism. These methods involve a variety of
techniques, such as treating the cells with high concentrations of
salt, an electric field, or detergent, to render the host cell
outer membrane or wall permeable to nucleic acid molecules of
interest, microinjection, PEG-fusion, and the like.
The term "promoter element" describes a nucleotide sequence that is
incorporated into a vector that, once inside an appropriate cell,
can facilitate transcription factor and/or polymerase binding and
subsequent transcription of portions of the vector DNA into mRNA.
In one embodiment, the promoter element of the present invention
precedes the 5' end of the asthma specific marker nucleic acid
molecule such that the latter is transcribed into mRNA. Host cell
machinery then translates mRNA into a polypeptide.
Those skilled in the art will recognize that a nucleic acid vector
can contain nucleic acid elements other than the promoter element
and the asthma specific marker encoding nucleic acid. These other
nucleic acid elements include, but are not limited to, origins of
replication, ribosomal binding sites, nucleic acid sequences
encoding drug resistance enzymes or amino acid metabolic enzymes,
and nucleic acid sequences encoding secretion signals, localization
signals, or signals useful for polypeptide purification.
A "replicon" is any genetic element, for example, a plasmid,
cosmid, bacmid, plastid, phage or virus, that is capable of
replication largely under its own control. A replicon may be either
RNA or DNA and may be single or double stranded.
An "expression operon" refers to a nucleic acid segment that may
possess transcriptional and translational control sequences, such
as promoters, enhancers, translational start signals (e.g., ATG or
AUG codons), polyadenylation signals, terminators, and the like,
and which facilitate the expression of a polypeptide coding
sequence in a host cell or organism.
As used herein, the terms "reporter," "reporter system", "reporter
gene," or "reporter gene product" shall mean an operative genetic
system in which a nucleic acid comprises a gene that encodes a
product that when expressed produces a reporter signal that is a
readily measurable, e.g., by biological assay, immunoassay, radio
immunoassay, or by colorimetric, fluorogenic, chemiluminescent or
other methods. The nucleic acid may be either RNA or DNA, linear or
circular, single or double stranded, antisense or sense polarity,
and is operatively linked to the necessary control elements for the
expression of the reporter gene product. The required control
elements will vary according to the nature of the reporter system
and whether the reporter gene is in the form of DNA or RNA, but may
include, but not be limited to, such elements as promoters,
enhancers, translational control sequences, poly A addition
signals, transcriptional termination signals and the like.
The introduced nucleic acid may or may not be integrated
(covalently linked) into nucleic acid of the recipient cell or
organism. In bacterial, yeast, plant and mammalian cells, for
example, the introduced nucleic acid may be maintained as an
episomal element or independent replicon such as a plasmid.
Alternatively, the introduced nucleic acid may become integrated
into the nucleic acid of the recipient cell or organism and be
stably maintained in that cell or organism and further passed on or
inherited to progeny cells or organisms of the recipient cell or
organism. Finally, the introduced nucleic acid may exist in the
recipient cell or host organism only transiently.
The term "selectable marker gene" refers to a gene that when
expressed confers a selectable phenotype, such as antibiotic
resistance, on a transformed cell.
The term "operably linked" means that the regulatory sequences
necessary for expression of the coding sequence are placed in the
DNA molecule in the appropriate positions relative to the coding
sequence so as to effect expression of the coding sequence. This
same definition is sometimes applied to the arrangement of
transcription units and other transcription control elements (e.g.
enhancers) in an expression vector.
The terms "recombinant organism," or "transgenic organism" refer to
organisms which have a new combination of genes or nucleic acid
molecules. A new combination of genes or nucleic acid molecules can
be introduced into an organism using a wide array of nucleic acid
manipulation techniques available to those skilled in the art. The
term "organism" relates to any living being comprised of a least
one cell. An organism can be as simple as one eukaryotic cell or as
complex as a mammal. Therefore, the phrase "a recombinant organism"
encompasses a recombinant cell, as well as eukaryotic and
prokaryotic organism.
The term "isolated protein" or "isolated and purified protein" is
sometimes used herein. This term refers primarily to a protein
produced by expression of an isolated nucleic acid molecule of the
invention. Alternatively, this term may refer to a protein that has
been sufficiently separated from other proteins with which it would
naturally be associated, so as to exist in "substantially pure"
form. "Isolated" is not meant to exclude artificial or synthetic
mixtures with other compounds or materials, or the presence of
impurities that do not interfere with the fundamental activity, and
that may be present, for example, due to incomplete purification,
addition of stabilizers, or compounding into, for example,
immunogenic preparations or pharmaceutically acceptable
preparations.
A "specific binding pair" comprises a specific binding member (sbm)
and a binding partner (bp) which have a particular specificity for
each other and which in normal conditions bind to each other in
preference to other molecules. Examples of specific binding pairs
are antigens and antibodies, ligands and receptors and
complementary nucleotide sequences. The skilled person is aware of
many other examples. Further, the term "specific binding pair" is
also applicable where either or both of the specific binding member
and the binding partner comprise a part of a large molecule. In
embodiments in which the specific binding pair comprises nucleic
acid sequences, they will be of a length to hybridize to each other
under conditions of the assay, preferably greater than 10
nucleotides long, more preferably greater than 15 or 20 nucleotides
long.
"Sample" or "patient sample" or "biological sample" generally
refers to a sample which may be tested for a particular molecule,
preferably an asthma specific marker molecule, such as a marker
shown in the tables provided below. Samples may include but are not
limited to cells, body fluids, including blood, serum, plasma,
urine, saliva, tears, pleural fluid and the like.
The terms "agent" and "test compound" are used interchangeably
herein and denote a chemical compound, a mixture of chemical
compounds, a biological macromolecule, or an extract made from
biological materials such as bacteria, plants, fungi, or animal
(particularly mammalian) cells or tissues. Biological
macromolecules include siRNA, shRNA, antisense oligonucleotides,
peptides, peptide/DNA complexes, and any nucleic acid based
molecule which exhibits the capacity to modulate the activity of
the SNP containing nucleic acids described herein or their encoded
proteins. Agents are evaluated for potential biological activity by
inclusion in screening assays described hereinbelow.
Methods of Using Asthma-Associated SNPs for Diagnosing a Propensity
for the Development of Asthma
Asthma-related-SNP containing nucleic acids, including but not
limited to those listed in the Tables provided below may be used
for a variety of purposes in accordance with the present invention.
Asthma-associated SNP containing DNA, RNA, or fragments thereof may
be used as probes to detect the presence of and/or expression of
asthma specific markers. Methods in which asthma specific marker
nucleic acids may be utilized as probes for such assays include,
but are not limited to: (1) in situ hybridization; (2) Southern
hybridization (3) northern hybridization; and (4) assorted
amplification reactions such as polymerase chain reactions
(PCR).
Further, assays for detecting asthma-associated SNPs or the
proteins encoded thereby may be conducted on any type of biological
sample, including but not limited to body fluids (including blood,
urine, serum, gastric lavage), any type of cell (such as brain
cells, white blood cells, mononuclear cells) or body tissue.
From the foregoing discussion, it can be seen that
asthma-associated SNP containing nucleic acids, vectors expressing
the same, asthma SNP containing marker proteins and anti-asthma
specific marker antibodies of the invention can be used to detect
asthma associated SNPs in body tissue, cells, or fluid, and alter
asthma SNP containing marker protein expression for purposes of
assessing the genetic and protein interactions involved in the
development of asthma.
In most embodiments for screening for asthma-associated SNPs, the
asthma-associated SNP containing nucleic acid in the sample will
initially be amplified, e.g. using PCR, to increase the amount of
the templates as compared to other sequences present in the sample.
This allows the target sequences to be detected with a high degree
of sensitivity if they are present in the sample. This initial step
may be avoided by using highly sensitive array techniques that are
becoming increasingly important in the art.
Alternatively, new detection technologies can overcome this
limitation and enable analysis of small samples containing as
little as 1 .mu.g of total RNA. Using Resonance Light Scattering
(RLS) technology, as opposed to traditional fluorescence
techniques, multiple reads can detect low quantities of mRNAs using
biotin labeled hybridized targets and anti-biotin antibodies.
Another alternative to PCR amplification involves planar wave guide
technology (PWG) to increase signal-to-noise ratios and reduce
background interference. Both techniques are commercially available
from Qiagen Inc. (USA).
Thus any of the aforementioned techniques may be used to detect or
quantify asthma-associated SNP marker expression and accordingly,
diagnose asthma.
Kits and Articles of Manufacture
Any of the aforementioned products can be incorporated into a kit
which may contain a asthma-associated SNP specific marker
polynucleotide or one or more such markers immobilized on a Gene
Chip, an oligonucleotide, a polypeptide, a peptide, an antibody, a
label, marker, or reporter, a pharmaceutically acceptable carrier,
a physiologically acceptable carrier, instructions for use, a
container, a vessel for administration, an assay substrate, or any
combination thereof.
Methods of Using Asthma-Associated SNPs for Development of
Therapeutic Agents
Since the SNPs identified herein have been associated with the
etiology of asthma, methods for identifying agents that modulate
the activity of the genes and their encoded products containing
such SNPs should result in the generation of efficacious
therapeutic agents for the treatment of this condition.
Chromosome 1 contains protein coding regions which provide suitable
targets for the rational design of therapeutic agents which
modulate their activity. Small peptide molecules corresponding to
these regions may be used to advantage in the design of therapeutic
agents which effectively modulate the activity of the encoded
proteins.
Molecular modeling should facilitate the identification of specific
organic molecules with capacity to bind to the active site of the
proteins encoded by the SNP containing nucleic acids based on
conformation or key amino acid residues required for function. A
combinatorial chemistry approach will be used to identify molecules
with greatest activity and then iterations of these molecules will
be developed for further cycles of screening. In certain
embodiments, candidate drugs can be screened from large libraries
of synthetic or natural compounds. One example is an FDA approved
library of compounds that can be used by humans. In addition,
compound libraries are commercially available from a number of
companies including but not limited to Maybridge Chemical Co.
(Trevillet, Cornwall, UK), Comgenex (Princeton, N.J.), Microsource
(New Milford, Conn.), Aldrich (Milwaukee, Wis.), AKos Consulting
and Solutions GmbH (Basel, Switzerland), Ambinter (Paris, France),
Asinex (Moscow, Russia), Aurora (Graz, Austria), BioFocus DPI,
Switzerland, Bionet (Camelford, UK), ChemBridge, (San Diego,
Calif.), ChemDiv, (San Diego, Calif.), Chemical Block Lt, (Moscow,
Russia), ChemStar (Moscow, Russia), Exclusive Chemistry, Ltd
(Obninsk, Russia), Enamine (Kiev, Ukraine), Evotec (Hamburg,
Germany), Indofine (Hillsborough, N.J.), Interbioscreen (Moscow,
Russia), Interchim (Montlucon, France), Life Chemicals, Inc.
(Orange, Conn.), Microchemistry Ltd. (Moscow, Russia), Otava,
(Toronto, ON), PharmEx Ltd.(Moscow, Russia), Princeton Biomolecular
(Monmouth Junction, N.J.), Scientific Exchange (Center Ossipee,
N.H.), Specs (Delft, Netherlands), TimTec (Newark, Del.), Toronto
Research Corp. (North York ON), UkrOrgSynthesis (Kiev, Ukraine),
Vitas-M, (Moscow, Russia), Zelinsky Institute, (Moscow, Russia),
and Bicoll (Shanghai, China).
Libraries of natural compounds in the form of bacterial, fungal,
plant and animal extracts are commercially available or can be
readily prepared by methods well known in the art. It is proposed
that compounds isolated from natural sources, such as animals,
bacteria, fungi, plant sources, including leaves and bark, and
marine samples may be assayed as candidates for the presence of
potentially useful pharmaceutical agents. It will be understood
that the pharmaceutical agents to be screened could also be derived
or synthesized from chemical compositions or man-made compounds.
Several commercial libraries can be used in the screens.
The polypeptides or fragments employed in drug screening assays may
either be free in solution, affixed to a solid support or within a
cell. One method of drug screening utilizes eukaryotic or
prokaryotic host cells which are stably transformed with
recombinant polynucleotides expressing the polypeptide or fragment,
preferably in competitive binding assays. Such cells, either in
viable or fixed form, can be used for standard binding assays. One
may determine, for example, formation of complexes between the
polypeptide or fragment and the agent being tested, or examine the
degree to which the formation of a complex between the polypeptide
or fragment and a known substrate is interfered with by the agent
being tested.
Another technique for drug screening provides high throughput
screening for compounds having suitable binding affinity for the
encoded polypeptides and is described in detail in Geysen, PCT
published application WO 84/03564, published on Sep. 13, 1984.
Briefly stated, large numbers of different, small peptide test
compounds, such as those described above, are synthesized on a
solid substrate, such as plastic pins or some other surface. The
peptide test compounds are reacted with the target polypeptide and
washed. Bound polypeptide is then detected by methods well known in
the art.
A further technique for drug screening involves the use of host
eukaryotic cell lines or cells (such as airway smooth muscle cells)
which have a nonfunctional or altered asthma associated gene. These
host cell lines or cells are defective at the polypeptide level.
The host cell lines or cells are grown in the presence of drug
compound. The rate of constriction or relaxation of the host cells
is measured to determine if the compound is capable of regulating
the airway responsiveness in the defective cells. Host cells
contemplated for use in the present invention include but are not
limited to bacterial cells, fungal cells, insect cells, mammalian
cells, and plant cells. The asthma-associated SNP encoding DNA
molecules may be introduced singly into such host cells or in
combination to assess the phenotype of cells conferred by such
expression. Methods for introducing DNA molecules are also well
known to those of ordinary skill in the art. Such methods are set
forth in Ausubel et al. eds., Current Protocols in Molecular
Biology, John Wiley & Sons, NY, N.Y. 1995, the disclosure of
which is incorporated by reference herein.
A wide variety of expression vectors are available that can be
modified to express the novel DNA sequences of this invention. The
specific vectors exemplified herein are merely illustrative, and
are not intended to limit the scope of the invention. Expression
methods are described by Sambrook et al. Molecular Cloning: A
Laboratory Manual or Current Protocols in Molecular Biology
16.3-17.44 (1989). Expression methods in Saccharomyces are also
described in Current Protocols in Molecular Biology (1989).
Suitable vectors for use in practicing the invention include
prokaryotic vectors such as the pNH vectors (Stratagene Inc., 11099
N. Torrey Pines Rd., La Jolla, Calif. 92037), pET vectors (Novogen
Inc., 565 Science Dr., Madison, Wis. 53711) and the pGEX vectors
(Pharmacia LKB Biotechnology Inc., Piscataway, N.J. 08854).
Examples of eukaryotic vectors useful in practicing the present
invention include the vectors pRc/CMV, pRc/RSV, and pREP
(Invitrogen, 11588 Sorrento Valley Rd., San Diego, Calif. 92121);
pcDNA3.1/V5&His (Invitrogen); baculovirus vectors such as
pVL1392, pVL1393, or pAC360 (Invitrogen); and yeast vectors such as
YRP17, YIP5, and YEP24 (New England Biolabs, Beverly, Mass.), as
well as pRS403 and pRS413 Stratagene Inc.); Picchia vectors such as
pHIL-D1 (Phillips Petroleum Co., Bartlesville, Okla. 74004);
retroviral vectors such as PLNCX and pLPCX (Clontech); and
adenoviral and adeno-associated viral vectors.
Promoters for use in expression vectors of this invention include
promoters that are operable in prokaryotic or eukaryotic cells.
Promoters that are operable in prokaryotic cells include lactose
(lac) control elements, bacteriophage lambda (pL) control elements,
arabinose control elements, tryptophan (trp) control elements,
bacteriophage T7 control elements, and hybrids thereof. Promoters
that are operable in eukaryotic cells include Epstein Barr virus
promoters, adenovirus promoters, SV40 promoters, Rous Sarcoma Virus
promoters, cytomegalovirus (CMV) promoters, baculovirus promoters
such as AcMNPV polyhedrin promoter, Picchia promoters such as the
alcohol oxidase promoter, and Saccharomyces promoters such as the
gal4 inducible promoter and the PGK constitutive promoter. In
addition, a vector of this invention may contain any one of a
number of various markers facilitating the selection of a
transformed host cell. Such markers include genes associated with
temperature sensitivity, drug resistance, or enzymes associated
with phenotypic characteristics of the host organisms.
Host cells expressing the asthma-associated SNPs of the present
invention or functional fragments thereof provide a system in which
to screen potential compounds or agents for the ability to modulate
the development of asthma. Thus, in one embodiment, the nucleic
acid molecules of the invention may be used to create recombinant
cell lines for use in assays to identify agents which modulate
aspects of aberrant cytokine signaling associated with asthma and
aberrant bronchoconstriction. Also provided herein are methods to
screen for compounds capable of modulating the function of proteins
encoded by SNP containing nucleic acids.
Another approach entails the use of phage display libraries
engineered to express fragment of the polypeptides encoded by the
SNP containing nucleic acids on the phage surface. Such libraries
are then contacted with a combinatorial chemical library under
conditions wherein binding affinity between the expressed peptide
and the components of the chemical library may be detected. U.S.
Pat. Nos. 6,057,098 and 5,965,456 provide methods and apparatus for
performing such assays.
The goal of rational drug design is to produce structural analogs
of biologically active polypeptides of interest or of small
molecules with which they interact (e.g., agonists, antagonists,
inhibitors) in order to fashion drugs which are, for example, more
active or stable forms of the polypeptide, or which, e.g., enhance
or interfere with the function of a polypeptide in vivo. See, e.g.,
Hodgson, (1991) Bio/Technology 9:19-21. In one approach, discussed
above, the three-dimensional structure of a protein of interest or,
for example, of the protein-substrate complex, is solved by x-ray
crystallography, by nuclear magnetic resonance, by computer
modeling or most typically, by a combination of approaches. Less
often, useful information regarding the structure of a polypeptide
may be gained by modeling based on the structure of homologous
proteins. An example of rational drug design is the development of
HIV protease inhibitors (Erickson et al., (1990) Science
249:527-533). In addition, peptides may be analyzed by an alanine
scan (Wells, (1991) Meth. Enzym. 202:390-411). In this technique,
an amino acid residue is replaced by Ala, and its effect on the
peptide's activity is determined. Each of the amino acid residues
of the peptide is analyzed in this manner to determine the
important regions of the peptide.
It is also possible to isolate a target-specific antibody, selected
by a functional assay, and then to solve its crystal structure. In
principle, this approach yields a pharmacore upon which subsequent
drug design can be based.
One can bypass protein crystallography altogether by generating
anti-idiotypic antibodies (anti-ids) to a functional,
pharmacologically active antibody. As a mirror image of a mirror
image, the binding site of the anti-ids would be expected to be an
analog of the original molecule. The anti-id could then be used to
identify and isolate peptides from banks of chemically or
biologically produced banks of peptides. Selected peptides would
then act as the pharmacore.
Thus, one may design drugs which have, e.g., improved polypeptide
activity or stability or which act as inhibitors, agonists,
antagonists, etc. of polypeptide activity. By virtue of the
availability of SNP containing nucleic acid sequences described
herein, sufficient amounts of the encoded polypeptide may be made
available to perform such analytical studies as x-ray
crystallography. In addition, the knowledge of the protein sequence
provided herein will guide those employing computer modeling
techniques in place of, or in addition to x-ray
crystallography.
In another embodiment, the availability of asthma-associated SNP
containing nucleic acids enables the production of strains of
laboratory mice carrying the asthma-associated SNPs of the
invention. Transgenic mice expressing the asthma-associated SNP of
the invention provide a model system in which to examine the role
of the protein encoded by the SNP containing nucleic acid in the
development and progression towards asthma. Methods of introducing
transgenes in laboratory mice are known to those of skill in the
art. Three common methods include: 1. integration of retroviral
vectors encoding the foreign gene of interest into an early embryo;
2. injection of DNA into the pronucleus of a newly fertilized egg;
and 3. the incorporation of genetically manipulated embryonic stem
cells into an early embryo. Production of the transgenic mice
described above will facilitate the molecular elucidation of the
role that a target protein plays in various processes associated
with the asthmatic phenotype, including: aberrant
bronchoconstriction, airway inflammation and altered IgE
production. Such mice provide an in vivo screening tool to study
putative therapeutic drugs in a whole animal model and are
encompassed by the present invention.
The term "animal" is used herein to include all vertebrate animals,
except humans. It also includes an individual animal in all stages
of development, including embryonic and fetal stages. A "transgenic
animal" is any animal containing one or more cells bearing genetic
information altered or received, directly or indirectly, by
deliberate genetic manipulation at the subcellular level, such as
by targeted recombination or microinjection or infection with
recombinant virus. The term "transgenic animal" is not meant to
encompass classical cross-breeding or in vitro fertilization, but
rather is meant to encompass animals in which one or more cells are
altered by or receive a recombinant DNA molecule. This molecule may
be specifically targeted to a defined genetic locus, be randomly
integrated within a chromosome, or it may be extrachromosomally
replicating DNA. The term "germ cell line transgenic animal" refers
to a transgenic animal in which the genetic alteration or genetic
information was introduced into a germ line cell, thereby
conferring the ability to transfer the genetic information to
offspring. If such offspring, in fact, possess some or all of that
alteration or genetic information, then they, too, are transgenic
animals.
The alteration of genetic information may be foreign to the species
of animal to which the recipient belongs, or foreign only to the
particular individual recipient, or may be genetic information
already possessed by the recipient. In the last case, the altered
or introduced gene may be expressed differently than the native
gene. Such altered or foreign genetic information would encompass
the introduction of asthma-associated SNP containing nucleotide
sequences.
The DNA used for altering a target gene may be obtained by a wide
variety of techniques that include, but are not limited to,
isolation from genomic sources, preparation of cDNAs from isolated
mRNA templates, direct synthesis, or a combination thereof.
A preferred type of target cell for transgene introduction is the
embryonal stem cell (ES). ES cells may be obtained from
pre-implantation embryos cultured in vitro (Evans et al., (1981)
Nature 292:154-156; Bradley et al., (1984) Nature 309:255-258;
Gossler et al., (1986) Proc. Natl. Acad. Sci. 83:9065-9069).
Transgenes can be efficiently introduced into the ES cells by
standard techniques such as DNA transfection or by
retrovirus-mediated transduction. The resultant transformed ES
cells can thereafter be combined with blastocysts from a non-human
animal. The introduced ES cells thereafter colonize the embryo and
contribute to the germ line of the resulting chimeric animal.
One approach to the problem of determining the contributions of
individual genes and their expression products is to use isolated
asthma-associated SNP genes as insertional cassettes to selectively
inactivate a wild-type gene in totipotent ES cells (such as those
described above) and then generate transgenic mice. The use of
gene-targeted ES cells in the generation of gene-targeted
transgenic mice was described, and is reviewed elsewhere (Frohman
et al., (1989) Cell 56:145-147; Bradley et al., (1992)
Bio/Technology 10:534-539).
Techniques are available to inactivate or alter any genetic region
to a mutation desired by using targeted homologous recombination to
insert specific changes into chromosomal alleles. However, in
comparison with homologous extrachromosomal recombination, which
occurs at a frequency approaching 100%, homologous
plasmid-chromosome recombination was originally reported to only be
detected at frequencies between 10.sup.-6 and 10.sup.-3.
Nonhomologous plasmid-chromosome interactions are more frequent
occurring at levels 10.sup.5-fold to 10.sup.2 fold greater than
comparable homologous insertion.
To overcome this low proportion of targeted recombination in murine
ES cells, various strategies have been developed to detect or
select rare homologous recombinants. One approach for detecting
homologous alteration events uses the polymerase chain reaction
(PCR) to screen pools of transformant cells for homologous
insertion, followed by screening of individual clones.
Alternatively, a positive genetic selection approach has been
developed in which a marker gene is constructed which will only be
active if homologous insertion occurs, allowing these recombinants
to be selected directly. One of the most powerful approaches
developed for selecting homologous recombinants is the
positive-negative selection (PNS) method developed for genes for
which no direct selection of the alteration exists. The PNS method
is more efficient for targeting genes which are not expressed at
high levels because the marker gene has its own promoter.
Non-homologous recombinants are selected against by using the
Herpes Simplex virus thymidine kinase (HSV-TK) gene and selecting
against its nonhomologous insertion with effective herpes drugs
such as gancyclovir (GANC) or (1-(2-deoxy-2-fluoro-B-D
arabinofluranosyl)-5-iodou-racil, (FIAU). By this counter
selection, the number of homologous recombinants in the surviving
transformants can be increased. Utilizing asthma-associated SNP
containing nucleic acid as a targeted insertional cassette provides
means to detect a successful insertion as visualized, for example,
by acquisition of immunoreactivity to an antibody immunologically
specific for the polypeptide encoded by asthma-associated SNP
nucleic acid and, therefore, facilitates screening/selection of ES
cells with the desired genotype.
As used herein, a knock-in animal is one in which the endogenous
murine gene, for example, has been replaced with human
asthma-associated SNP containing gene of the invention. Such
knock-in animals provide an ideal model system for studying the
development of asthma.
As used herein, the expression of a asthma-associated SNP
containing nucleic acid, fragment thereof, or an asthma-associated
SNP fusion protein can be targeted in a "tissue specific manner" or
"cell type specific manner" using a vector in which nucleic acid
sequences encoding all or a portion of asthma-associated SNP are
operably linked to regulatory sequences (e.g., promoters and/or
enhancers) that direct expression of the encoded protein in a
particular tissue or cell type. Such regulatory elements may be
used to advantage for both in vitro and in vivo applications.
Promoters for directing tissue specific proteins are well known in
the art and described herein.
The nucleic acid sequence encoding the asthma-associated SNP of the
invention may be operably linked to a variety of different promoter
sequences for expression in transgenic animals. Such promoters
include, but are not limited to a prion gene promoter such as
hamster and mouse Prion promoter (MoPrP), described in U.S. Pat.
No. 5,877,399 and in Borchelt et al., Genet. Anal. 13(6) (1996)
pages 159-163; a rat neuronal specific enolase promoter, described
in U.S. Pat. Nos. 5,612,486, and 5,387,742; a platelet-derived
growth factor B gene promoter, described in U.S. Pat. No.
5,811,633; a brain specific dystrophin promoter, described in U.S.
Pat. No. 5,849,999; a Thy-1 promoter; a PGK promoter; and a CMV
promoter for the expression of transgenes in airway smooth muscle
cells.
Methods of use for the transgenic mice of the invention are also
provided herein. Transgenic mice into which a nucleic acid
containing the asthma-associated SNP or its encoded protein have
been introduced are useful, for example, to develop screening
methods to screen therapeutic agents to identify those capable of
modulating the development of asthma.
Pharmaceuticals and Methods of Treatment
The elucidation of the role played by the asthma associated SNPs
described herein in modulating the asthmatic phenotype facilitates
the development of pharmaceutical compositions useful for treatment
and diagnosis of asthma. These compositions may comprise, in
addition to one of the above substances, a pharmaceutically
acceptable excipient, carrier, buffer, stabilizer or other
materials well known to those skilled in the art. Such materials
should be non-toxic and should not interfere with the efficacy of
the active ingredient. The precise nature of the carrier or other
material may depend on the route of administration, e.g. oral,
intravenous, cutaneous or subcutaneous, nasal, aerosolized,
intramuscular, and intraperitoneal routes.
The invention includes a method of treating asthma in a mammal. An
exemplary method entails administering to the mammal a
pharmaceutically effective amount of DENND1B siRNA. See Table 13.
The siRNA inhibits the expression of DENND1B. Preferably, the
mammal is a human. The term "patient" as used herein refers to a
human.
Specific siRNA preparations directed at inhibiting the expression
of DENND1B, as well as delivery methods are provided as a novel
therapy to treat asthma. SiRNA oligonucleotides directed to DENND1B
specifically hybridize with nucleic acids encoding DENND1B and
interfere with DENND1B gene expression. The siRNA can be delivered
to a patient in vivo either systemically or locally with carriers,
as discussed below. The compositions of the invention may be used
alone or in combination with other agents or genes encoding
proteins to augment the efficacy of the compositions.
A "membrane permeant peptide sequence" refers to a peptide sequence
which is able to facilitate penetration and entry of the DENND1B
inhibitor across the cell membrane. Exemplary peptides include with
out limitation, the signal sequence from Karposi fibroblast growth
factor exemplified herein, the HIV tat peptide (Vives et al., J
Biol. Chem., 272:16010-16017, 1997), Nontoxic membrane
translocation peptide from protamine (Park et al., FASEB J.
19(11):1555-7, 2005), CHARIOT.RTM. delivery reagent (Active Motif;
U.S. Pat. No. 6,841,535) and the antimicrobial peptide Buforin
2.
In one embodiment of the invention siRNAs are delivered for
therapeutic benefit. There are several ways to administer the siRNA
of the invention to in vivo to treat asthma including, but not
limited to, naked siRNA delivery, siRNA conjugation and delivery,
liposome carrier-mediated delivery, polymer carrier delivery,
nanoparticle compositions, plasmid-based methods, and the use of
viruses.
siRNA composition of the invention can comprise a delivery vehicle,
including liposomes, for administration to a subject, carriers and
diluents and their salts, and/or can be present in pharmaceutically
acceptable formulations. This can be necessary to allow the siRNA
to cross the cell membrane and escape degradation. Methods for the
delivery of nucleic acid molecules are described in Akhtar et al.,
1992, Trends Cell Bio., 2, 139; Delivery Strategies for Antisense
Oligonucleotide Therapeutics, ed. Akhtar, 1995, Maurer et al.,
1999, Mol. Membr. Biol., 16, 129-140; Hofland and Huang, 1999,
Handb. Exp. Pharmacol., 137, 165-192; and Lee et al., 2000, ACS
Symp. Ser., 752, 184-192; Beigelman et al., U.S. Pat. No. 6,395,713
and Sullivan et al., PCT WO 94/02595 further describe the general
methods for delivery of nucleic acid molecules. These protocols can
be utilized for the delivery of virtually any nucleic acid
molecule.
The frequency of administration of the siRNA to a patient will also
vary depending on several factors including, but not limited to,
the type and severity of the asthma to be treated, the route of
administration, the age and overall health of the individual, the
nature of the siRNA, and the like. It is contemplated that the
frequency of administration of the siRNA to the patient may vary
from about once every few months to about once a month, to about
once a week, to about once per day, to about several times
daily.
Pharmaceutical compositions that are useful in the methods of the
invention may be administered systemically in parenteral, oral
solid and liquid formulations, ophthalmic, suppository, aerosol,
topical or other similar formulations. In addition to the
appropriate siRNA, these pharmaceutical compositions may contain
pharmaceutically-acceptable carriers and other ingredients known to
enhance and facilitate drug administration. Thus such compositions
may optionally contain other components, such as adjuvants, e.g.,
aqueous suspensions of aluminum and magnesium hydroxides, and/or
other pharmaceutically acceptable carriers, such as saline. Other
possible formulations, such as nanoparticles, liposomes, resealed
erythrocytes, and immunologically based systems may also be used to
administer the appropriate siRNA to a patient according to the
methods of the invention. The use of nanoparticles to deliver
siRNAs, as well as cell membrane permeable peptide carriers that
can be used are described in Crombez et al., Biochemical Society
Transactions v35:p44 (2007).
Methods of the invention directed to treating asthma involve the
administration of DENND1B siRNA in a pharmaceutical composition.
DENND1B siRNA is administered to an individual as a pharmaceutical
composition comprising DENND1B siRNA and a pharmaceutically
acceptable carrier. Pharmaceutically acceptable carriers are well
known in the art and include aqueous solutions such as
physiologically buffered saline, other solvents or vehicles such as
glycols, glycerol, oils such as olive oil or injectable organic
esters.
A pharmaceutically acceptable carrier can contain physiologically
acceptable compounds that act, for example, to stabilize the
DENND1B siRNA or increase the absorption of the agent. Such
physiologically acceptable compounds include, for example,
carbohydrates, such as glucose, sucrose or dextrans, antioxidants,
such as ascorbic acid or glutathione, chelating agents, low
molecular weight proteins or other stabilizers or excipients. One
skilled in the art would know that the choice of a pharmaceutically
acceptable carrier, including a physiologically acceptable
compound, depends, for example, on the route of administration of
the DENND1B siRNA.
One skilled in the art appreciates that a pharmaceutical
composition comprising DENND1B siRNA can be administered to a
subject by various routes including, for example, orally or
parenterally, such as intravenously (i.v.), intramuscularly,
subcutaneously, intraorbitally, intranasally, intracapsularly,
intraperitoneally (i.p.), intracisternally, intra-tracheally
(i.t.), or intra-articularly or by passive or facilitated
absorption. The same routes of administration can be used other
pharmaceutically useful compounds, for example, small molecules,
nucleic acid molecules, peptides, antibodies and polypeptides as
discussed hereinabove.
A pharmaceutical composition comprising DENND1B siRNA inhibitor
also can be incorporated, if desired, into liposomes, microspheres,
microbubbles, or other polymer matrices (Gregoriadis, Liposome
Technology, Vols. I to III, 2nd ed., CRC Press, Boca Raton Fla.
(1993)). Liposomes, for example, which consist of phospholipids or
other lipids, are nontoxic, physiologically acceptable and
metabolizable carriers that are relatively simple to make and
administer.
The pharmaceutical preparation comprises a siRNA targeting DENND1B
or an expression vector encoding for an siRNA targeting DENND1B.
Such pharmaceutical preparations can be administered to a patient
for treating asthma.
Expression vectors for the expression of siRNA molecules preferably
employ a strong promoter which may be constitutive or regulated.
Such promoters are well known in the art and include, but are not
limited to, RNA polymerase II promoters, the T7 RNA polymerase
promoter, and the RNA polymerase III promoters U6 and H1 (see,
e.g., Myslinski et al. (2001) Nucl. Acids Res., 29:2502 09).
A formulated siRNA composition can be a composition comprising one
or more siRNA molecules or a vector encoding one or more siRNA
molecules independently or in combination with a cationic lipid, a
neutral lipid, and/or a polyethyleneglycol-diacylglycerol (PEG-DAG)
or PEG-cholesterol (PEG-Chol) conjugate. Non-limiting examples of
expression vectors are described in Paul et al., 2002, Nature
Biotechnology, 19, 505; Miyagishi and Taira, 2002, Nature
Biotechnology, 19, 497; Lee et al., 2002, Nature Biotechnology, 19,
500-505.
A lipid nanoparticle composition is a composition comprising one or
more biologically active molecules independently or in combination
with a cationic lipid, a neutral lipid, and/or a
polyethyleneglycol-diacylglycerol (i.e., polyethyleneglycol
diacylglycerol (PEG-DAG), PEG-cholesterol, or PEG-DMB) conjugate.
In one embodiment, the biologically active molecule is encapsulated
in the lipid nanoparticle as a result of the process of providing
and aqueous solution comprising a biologically active molecule of
the invention (i.e., siRNA), providing an organic solution
comprising lipid nanoparticle, mixing the two solutions, incubating
the solutions, dilution, ultrafiltration, resulting in
concentrations suitable to produce nanoparticle compositions.
Nucleic acid molecules can be administered to cells by
incorporation into other vehicles, such as biodegradable polymers,
hydrogels, cyclodextrins. (see for example Gonzalez et al., 1999,
Bioconjugate Chem., 10, 1068-1074; Wang et al., International PCT
publication Nos. WO 03/47518 and WO 03/46185),
poly(lactic-co-glycolic)acid (PLGA) and PLCA microspheres (see for
example U.S. Pat. No. 6,447,796 and U.S. Patent Application
Publication No. US 2002130430), biodegradable nanocapsules, and
bioadhesive microspheres, or by proteinaceous vectors (O'Hare and
Normand, International PCT Publication No. WO 00/53722)
Cationic lipids and polymers are two classes of non-viral siRNA
delivery which can form complexes with negatively charged siRNA.
The self-assembly PEG-ylated polycation polyethylenimine (PEI) has
also been used to condense and protect siRNAs (Schiffelers et al.,
2004, Nuc. Acids Res. 32: 141-110). The siRNA complex can be
condensed into a nanoparticle to allow efficient uptake of the
siRNA through endocytosis. Also, the nucleic acid-condensing
property of protamine has been combined with specific antibodies to
deliver siRNAs and can be used in the invention (Song et al., 2005,
Nat Biotech. 23:709-717).
In order to treat an individual having asthma to alleviate a sign
or symptom of the disease, DENND1B siRNA should be administered in
an effective dose. The total treatment dose can be administered to
a subject as a single dose or can be administered using a
fractionated treatment protocol, in which multiple doses are
administered over a more prolonged period of time, for example,
over the period of a day to allow administration of a daily dosage
or over a longer period of time to administer a dose over a desired
period of time. One skilled in the art would know that the amount
of DENND1B siRNA required to obtain an effective dose in a subject
depends on many factors, including the age, weight and general
health of the subject, as well as the route of administration and
the number of treatments to be administered. In view of these
factors, the skilled artisan would adjust the particular dose so as
to obtain an effective dose for treating an individual having
asthma.
The effective dose of DENND1B siRNA will depend on the mode of
administration, and the weight of the individual being treated. The
dosages described herein are generally those for an average adult
but can be adjusted for the treatment of children. The dose will
generally range from about 0.001 mg to about 1000 mg.
The concentration of DENND1B siRNA in a particular formulation will
depend on the mode and frequency of administration. A given daily
dosage can be administered in a single dose or in multiple doses so
long as the DENND1B siRNA concentration in the formulation results
in the desired daily dosage. One skilled in the art can adjust the
amount of DENND1B siRNA in the formulation to allow administration
of a single dose or in multiple doses that provide the desired
concentration of DENND1B siRNA over a given period of time.
In an individual suffering from asthma, in particular a more severe
form of the disease, administration of DENND1B siRNA can be
particularly useful when administered in combination, for example,
with a conventional agent for treating such a disease. The skilled
artisan would administer DENND1B siRNA, alone or in combination and
would monitor the effectiveness of such treatment using routine
methods such as pulmonary function determination, radiologic,
immunologic or, where indicated, histopathologic methods. Other
conventional agents for the treatment of asthma include steroid or
administration of other agents that alleviate the symptoms
underlying the disease.
Administration of the pharmaceutical preparation is preferably in
an "effective amount" this being sufficient to show benefit to the
individual. This amount prevents, alleviates, abates, or otherwise
reduces the severity of asthma symptoms in a patient.
The pharmaceutical preparation is formulated in dosage unit form
for ease of administration and uniformity of dosage. Dosage unit
form, as used herein, refers to a physically discrete unit of the
pharmaceutical preparation appropriate for the patient undergoing
treatment. Each dosage should contain a quantity of active
ingredient calculated to produce the desired effect in association
with the selected pharmaceutical carrier. Procedures for
determining the appropriate dosage unit are well known to those
skilled in the art.
Dosage units may be proportionately increased or decreased based on
the weight of the patient. Appropriate concentrations for
alleviation of a particular pathological condition may be
determined by dosage concentration curve calculations, as known in
the art.
The following example is provided to illustrate certain embodiments
of the invention. It is not intended to limit the invention in any
way.
EXAMPLE I
Identification of Asthma Associated SNPs in a Pediatric
Population
We carried out a genome wide association study in a cohort of
pediatric asthma patients and matched controls consisting of 793
North American cases of European ancestry (EA) with persistent
asthma requiring daily inhaled glucocorticoids for symptom control,
and 1988 matched control subjects without asthma. The association
results were replicated in an independent set of 917 EA asthma
cases and 1546 matched controls. We also analyzed and report on
1667 children of African-American (AA) ancestry with physician
diagnosed asthma and 2045 AA controls.
In addition to replicating the previously reported ORMDL3 locus on
17q21 in our meta-analysis, eight SNPs at 1q31 reached genome-wide
significance in the Caucasian discovery cohort, top SNP rs2786098
(P=8.5.times.10.sup.-9, OR=0.63) and replicated in the independent
EA cohort (combined P=9.3.times.10.sup.-11, OR=0.70). The same SNPs
were also strongly associated with asthma in the AA children
(combined P across all samples 1.6.times.10.sup.-13), albeit with
the alternate allele due to allele tagging differences and
heterogeneity in the local patterns of linkage disequilibrium
between these populations. The associated interval contains
DENND1B, a gene expressed by natural killer cells and dendritic
cells that encodes a protein predicted to interact with the
TNF.alpha. receptor, whose family members are known to regulate
neurotransmitter release and exocytosis in neuronal cells.
The following material and methods are provided to facilitate the
practice of Example I.
This study was approved by the institutional review board of the
Children's Hospital of Philadelphia (CHOP). Parental informed
consent was obtained from all participants in this study for the
purpose of DNA collection and genotyping.
Study Subjects
The asthma discovery cohort consisted of 793 patients of European
ancestry (EA) recruited at CHOP. The mean age of these cases was
7.4.+-.4.5 SD years and 53% were males. All the subjects had
persistent asthma necessitating regular administration of
glucocorticoid medications for symptom control. Disease severity
matched steps 2-6 as reported in the Asthma Expert Panel-3
guidelines.sup.11.
The combined EA replication cohort consisted of 917 patients with
physician-diagnosed asthma who were recruited from three different
study sites: 1) 343 unrelated patients (parents and children) from
the Copenhagen Prospective Study on Asthma in Childhood (COPSAC) in
Denmark with asthma diagnosed during childhood.sup.12,13; 2) 410
unrelated children from the German MAGIC cohort with history of
recurrent asthma exacerbations and hospitalizations.sup.6 and; 3)
164 unrelated children from the British MRCA cohort diagnosed with
severe asthma.sup.6 (Table 1). COPSAC is a single-center birth
cohort study of children of asthmatic mothers. We genotyped 304
mothers all of whom had physician diagnosed asthma by the age of 7
years; 35 fathers with physician-diagnosed asthma during childhood;
and 4 children diagnosed with moderate to severe asthma at the age
of 6 years. These children were unrelated to the parents used in
the study. The COPSAC patients have been extensively phenotyped as
described previously.sup.12,13. The German MAGIC subjects included
in this study matched closely the phenotypic severity level and
demographic profile of the discovery cohort .The British MRCA
cohort consist of multiplex families with severe asthma; only one
individual per family was used in this study. Population details
and genotyping procedures for the MRCA and MAGIC cohorts have been
previously reported.sup.6.
The African American (AA) cohort consisted of 1667 cases with
physician diagnosed asthma, 1223 of whom were recruited at CHOP and
444 at Johns Hopkins and Howard University. The mean age of these
cases was 7.4.+-.SD 5.7 years and 57% were males.
The control groups used in the discovery phase included 1988
self-reported Caucasian children of European ancestry who were
recruited at CHOP (mean age was 8.5.+-.5.6 SD years and 50% male).
The replication control group included 210 Danish samples with no
history of asthma collected as part of the COPSAC study and 1336
British samples genotyped by the Wellcome Trust Case Control
Consortium (www.b58cgene.sgul.ac.uk). The African American controls
consisted of 2045 children of self-reported AA ancestry 1652 of
whom were recruited at CHOP and 393 at Johns Hopkins (mean age was
6.6.+-.7.7 SD years and 49% were males). CHOP patients and controls
were recruited by CHOP clinicians and nursing staff within the CHOP
Health Care Network, including four primary care clinics and
several group practices and outpatient practices that included well
child visits. All CHOP controls screened negative for asthma or
reactive airway diseases based on questionnaire information (Table
1).
For a secondary analysis of age of onset, we surveyed the
electronic medical records database at CHOP taking the date of
first asthma diagnosis or first prescription of asthma-specific
medication as the approximate date of asthma onset. A total of 793
EA cases and 2109 AA cases ranging in age from 2 to 19 years were
included in the analysis.
To reduce the risk of population stratification due to inaccurate
self-reported ancestry all internal patients and controls were
initially screened using the STRUCTURE package.sup.14, we used 220
ancestry informative markers (AIMs) and spiked the test sample set
with 90 CEPH, Yoruban and Chinese/Japanese individuals genotyped as
part of the HapMap project to improve clustering. Samples were
excluded from the EA set if their inferred proportion of ancestry
was less than 90% that of the CEU cluster and from the AA set if it
was less than 70% of the Yoruban cluster. All Asian samples were
excluded from the analysis.
To minimize confounding due to population stratification, each set
of cases was matched to its respective set of controls by `genetic
matching` as previously described.sup.15. `Genetic matching` is a
principal component analysis (PCA) based method of matching cases
with controls that minimizes the effects of population
stratification in GWA studies. We computed principal components for
our dataset by running smart pca, a part of the EIGENSTRAT package,
on 100,000 random autosomal SNPs and applied a matching algorithm
implemented in MATLAB to the output. The matching algorithm assigns
each sample a coordinate based on k eigen value-scaled principal
components. It then matches each case to m unique controls within a
distance d, keeping only cases that match exactly m controls. The
distance thresholds were manually optimized for each data set to
minimize GIF and maximize power (i.e. number of cases). In this
study, we matched the CHOP discovery cases to 3 controls, using 3
principal components and a distance threshold of 0.07. African
American cases were matched to 2 controls at a distance threshold
of 0.05 and the replication cohort cases were matched to 2 controls
at a distance threshold of 0.04.
Genotyping
All CHOP and COPSAC samples were genotyped on the Illumina HH550
BeadChip. The Johns Hopkins and Howard University AA samples were
genotyped on the Illumina 650Y Bead Chip. The MRCA, MAGIC and ISAAC
samples were genotyped on HH300 Bead Chip as previously
described.sup.6. The 1958 birth cohort samples were genotyped on
the HH550 Bead Chip by the Wellcome Trust Case Control Consortium
(WTCCC).sup.4.
We performed high throughput genome-wide SNP genotyping, using the
Illumina Infinium.TM. II HumanHap550 BeadChip technology.sup.16,17
(Illumina, San Diego) at the Center for Applied Genomics at CHOP,
as previously described.sup.18. Quality control values for the
individual data sets are presented in Table 4.
Statistical Analysis
Statistical tests for association were carried out using the
software package plink
(http://pngu.mgh.harvard.edu/.about.purcell/plink/index.shtml) for
genotyped SNPs and SNPTEST.sup.19 when imputed SNPs were included
in the analyses to take the genotype uncertainty introduced by the
imputation into account, a call threshold of 0.9 was used, SNPs
with an info score below 0.5 were excluded. Single marker analyses
for the genome-wide data were carried out using the
Cochran-Armitage trend. Combined P-values across the Caucasian data
sets were obtained using both Fisher's method and fixed-effect
meta-analyses as implemented in the R package "meta". To combine
the Caucasian data set and the African American data set in a joint
analysis, the logistic regression model was fitted to include an
additional predictor variable for race by genotype interactions in
view of the observed differences in directionality of effect
between these two populations at this locus.
Imputation of untyped markers (.about.2M) was carried out using
IMPUTE.sup.19. Reference phased CEU haplotypes and recombination
rates were obtained from the HapMap project; Phase II build 22.
Imputation was carried out in 1 Mb intervals using an effective
population size of 11418 as recommended. Over 99% of genotypes
would have been called with over 96% concordance across all runs at
a call threshold of 0.5.
Conditional SNP regression analyses were carried out in plink, the
allele dosages of the conditioning SNP were included as covariates
in the logistic regression models. For the age of onset analysis,
we performed an analysis of variance (ANOVA) with the general
linear models procedure in R (www.r-project.org),Independent
variables for each ANOVA were the log transformed age of onset and
the individual SNP genotype with additive encoding.
Results
We performed a GWA study in 793 North American children of European
ancestry with physician-diagnosed asthma necessitating daily
corticosteroid administration for symptom control and 1988
disease-free controls. Cochran-Armitage trend test statistics were
calculated at all markers following quality control filtering. In
addition to self-reported ancestry, all cases and controls were
initially screened at ancestry informative markers (AIMs) using the
STRUCTURE software package to reduce the risk of population
stratification due to misspecification of self-reported ancestry.
Cases were subsequently `genetically matched` to controls by
principal component analysis as previously described.sup.15.
Eight SNPs reached genome-wide significance following Bonferroni
correction for multiple testing. All eight SNPs mapped to a 540 kb
interval on 1q31.3 (top marker, rs2786098 MAFs 15.2% in cases and
22.2% in controls, OR=0.63, [95% CI 0.54-0.73],
P=8.55.times.10.sup.-9). The interval contained a further 12
markers in strong linkage disequilibrium (LD) (r.sup.2>0.45)
that also showed strong evidence of association (P-value
range=2.1.times.10.sup.-5-1.4.times.10.sup.-7; OR range=0.62-0.67)
(Table 2). All 20 associated SNPs map to asingle LD block that
spans the DENND1B (DENN/MADD domain containing 1 B)gene as well as
the 3' end of the CRB1 (drosophila crumbs homolog 1)gene (FIG. 1).
Imputation of a further 2 M untyped SNPs genome-wide yielded an
additional 102 SNPs in the chromosome 1q31 LD block that were
significantly associated with asthma. Eight imputed markers were
more significantly associated than rs2786098, the top performing
genotyped SNP, (P-values range
7.05.times.10.sup.-9-9.77.times.10.sup.-5; OR range 0.62-0.78)
(Table 6). No other imputed SNPs reached genome-wide
significance.
We next sought to replicate the findings in an independent sample
of pediatric asthma cases of European ancestry. We analyzed a
combined cohort of 917 pediatric onset Northern European asthma
patients from three different study sites and 1546 control samples
(Table 1). There was no overlap between the patients or controls in
the discovery and replication sets. Two of the replication sets
were genotyped on the HH300K Bead Chips, the combined analysis was
therefore carried out on approximately 317,000 SNPs that were
common to the HH550 and HH300 Bead Chips and the missing SNPs
imputed. All reported P-values were corrected for the genotype
uncertainty that is introduced by the imputation. To reduce the
effects of population stratification we `genetically matched` cases
to controls by principal component analysis as previously
described.sup.15.
Of the twenty associated SNPs in the discovery cohort, eighteen
were significantly associated with asthma (P-value
range=0.043-6.5.times.10.sup.-4; OR range=0.69-0.89) (Tables 2 and
6). The most significantly associated SNP across both Caucasian
cohorts following the combination of P-values by Fisher's method
and a fixed effects meta-analysis remained rs2786098
(P-value=3.9.times.10.sup.-11; OR 0.7 95% CI 0.63-0.78). Results of
the individual replication sets are presented in Table 7.
We subsequently carried out a combined analysis of all the European
ancestry asthma cases and controls on the 2 million imputed and
genotyped SNPs. Apart from the previously reported 17q21 locus and
the 1q31 locus, one SNP at 6q27 surpassed the genome-wide threshold
for significance. Two other loci at 3p12 and 9p23 showed a trend
for association (FIG. 2, Table 10).
To determine if this locus also contributes to asthma in children
of African ancestry, we tested the interval for association in a
large pediatric cohort of 1667 AA subjects with physician-diagnosed
asthma and 2045 disease-free controls. Seventeen of the twenty
markers were significantly associated with asthma, albeit with the
alternate allele (P-value range=0.01-4.2.times.10.sup.-7; OR
range=0.53-0.96) (Tables 2 and 11). Following the combination of
P-values across all three samples sets using a joint test of the
SNP effect and SNP race interaction, rs2786098 remained the most
strongly associated (P-value=1.68.times.10.sup.-13; Table 2).
Plotting the r.sup.2 within the associated interval in the AA CHOP
control samples showed marked degradation in the LD structure
compared to EA discovery control samples (FIGS. 1 and 3). The most
significant association in the AA cohort was with a small block of
LD formed by four SNPs in intron 2 of DENND1B (rs1747815,
rs1775456, rs1924518 and rs1775444, P-value
range=3.1.times.10.sup.-7-9.4.times.10.sup.-7; OR=0.53) (Table 2).
However, the association extended over the same interval as the EA
samples. We therefore sought to determine if there was more than
one SNP with independent effects in the interval in the African
American samples. We carried out logistic regression analyses in
the EA and AA samples conditioning on the most significantly
associated SNP in the Caucasians, rs2786098. The conditional
analysis in the EA samples effectively nullified the association in
the interval whereas ten SNPs remained significantly associated in
the AA set, the most significant of which was rs1775456 (P-value
2.4.times.10.sup.-4) (Table 3). Conditioning on rs1775456 nullified
the association in both EA and AA samples suggesting that the
associated variant is in the proximity of rs1775456.
Finally, to further investigate the observed association with
asthma we analyzed the EA and AA cases for age of onset effects. In
both EA and AA samples there was a significant difference in the
distribution of genotypes assuming an additive model according to
age of onset, 9 SNPs were significant following ANOVA in the EAs
and 3 in the AAs (Table 12). In the EAs the protective minor allele
homozygotes were more frequent in the patients with later ages of
onset, whereas in the African Americans the effect was reversed
with an increased frequency of the risk ancestral homozyotes in the
younger onset cases.
Discussion
We have identified and replicated a genome-wide significant locus
at 1q31 in asthma patients of Northern European ancestry and also
observed association in an asthma cohort of African ancestry at
this same locus. The association in the African Americans was
observed with the opposite allele to that of the EA samples. Our
investigations into the observed risk allele reversal in the
African Americans suggest that at least one of the tagged causal
variants may have arisen independently. Allele reversal at a shared
causal variant can be attributed to the considerable differences in
the underlying genomic architectures at this locus between
individuals of African and European ancestry, as previously
demonstrated.sup.20.
Two genes map to this locus CRB1 and DENND1B. Functionally, CRB1
encodes a transmembrane protein involved in the morphogenesis and
maintenance of the retina epithelia.sup.21. CRB1 mutations have
been shown to result in retinitis pigmentosa (RP12).sup.22.
Expression of the full length gene and its splice forms is
restricted to the retina and brain.sup.22,23. As such it is an
unlikely asthma candidate gene.
In contrast to CRB1, the DENND1B gene remains poorly characterized.
It encodes a DENN/MADD (differentially expressed in normal versus
neoplastic/mitogen-activated protein kinase-activating death)
domain first identified as a tumor necrosis factor (TNF) .alpha.
receptor type 1 (TNFR1) binding protein.sup.24. DENN/MADD is a part
of a signaling protein complex that is localized to the cytosol and
exerts multiple functions by using different binding partners
including TNFR1. DENN/MADD has been shown to act as a negative
regulator of TNFR1 signaling in response to cytokine-promoted
stress.sup.24, regulate recycling of small G proteins and play an
essential role in Ca.sup.2+-dependent neurotransmitter release and
exocytosis.sup.25.
DENND1B is expressed in a subset of dendritic cells (DCs),
BDCA3.sup.+DCs.sup.26 and BDCA4.sup.+DCs and natural killer (NK)
cells (FIG. 4).sup.27. DCs are a distinct lineage of leukocytes
that function as the gate-keepers of innate and adaptive immune
responses, by modulating tolerance or triggering immunity through
the release and regulation of various cytokines.sup.28.
Immunological memory is also a fundamental feature of the adaptive
immune system and DENND1B is significantly upregulated in effector
memory T cells compared to naive T cells .sup.29 suggesting a role
for DENND1B in the immune response to previously encountered
pathogens.
The cardinal features of asthma, airway inflammation and airway
hyperresponsiveness, both of which are associated with atopy and
elevated IgE levels, have been postulated to arise from an aberrant
T cell response to viral or bacterial infection or to common
allergens.sup.12. T cells are activated through exposure to
antigens on dendritic cell surfaces; in asthma a larger proportion
of activated T cells develop a T.sub.H2 pattern that results in the
expression of T cell survival cytokines such as IL-5 and
IL-13.sup.30. DENND1B, which is expressed on both DCs and activated
T cells, functions to downregulate TNFR1 signaling thereby
modulating the T.sub.H1-T.sub.H2 cytokine cascade and other
inflammatory signaling pathways.
In conclusion, we have identified a locus on chromosome 1q31 that
is significantly associated with moderate to severe persistent
asthma at the genome-wide level and replicates in independent
cohorts of asthma patients of different ethnic backgrounds,
including African Americans and Caucasians of Northern European
ancestry. Age of onset analysis indicates the variants predispose
to early onset asthma. The observed association in AA children
places this locus amongst a select few asthma genes, IL4, IL13,
CD14, ADRB2, FcER1B, AL4RA and most recently ORMDL3 (the only one
detected through GWA so far), that have been found to predispose to
asthma in multiple populations.sup.6, 31, 32, including our
own..sup.33 Of the two genes in the associated interval, the
DENND1B gene product has a putative role in the adaptive immune
system. As such the characterization of the role of DENND1B in
asthma together with other gene products in this network could lead
to a better understanding of the underlying disease etiology.
TABLE-US-00001 TABLE 1 Composition of the Discovery and Replication
cohorts and the Illumina Bead Chip on which they were genotyped.
Caucasian discovery cohort African American cohort Caucasian
Replication set CHOP CHOP JH Total COPSAC MAGIC/ISAAC MRCA WTCCC
Total Asthmatic 793 1223 444 1667 343 410 164 NA 917 Controls 1988
1652 393 2045 210 NA NA 1336 1546 Illumina HH550K HH550K HH650YK --
HH550K HH300K HH300K HH550K -- BeadChip
TABLE-US-00002 TABLE 2 Associated SNP P-values and odds ratios in
the CHOP EA discovery cohort, the combined replication set and the
African American (AA) samples. EA Combined Combined CHOP discovery
replication Caucasian AA All SNP Pos A1 Freq OR P OR P OR P A2 OR P
P *rs2786098 194057565 A 0.152 0.63 8.55 .times. 10.sup.-9 0.77
6.47 .times. 10.sup.-4 0.70 .sup. 9.33 .times. 10.sup.-11 C 0.71
3.77 .times. 10.sup.-5 1.68 .times. 10.sup.-13 rs2821106 194115942
A 0.0927 0.66 2.06 .times. 10.sup.-5 0.81 1.81 .times. 10.sup.-3
0.73 .sup. 6.32 .times. 10.sup.-06 G 0.49 3.52 .times. 10.sup.-5
2.01 .times. 10.sup.-9 *rs12134409 194123724 T 0.153 0.64 2.72
.times. 10.sup.-8 0.77 5.37 .times. 10.sup.-4 0.71 .sup. 1.64
.times. 10.sup.-10 C 0.66 3.80 .times. 10.sup.-5 7.30 .times.
10.sup.-13 rs2111931 194260875 C 0.147 0.65 8.71 .times. 10.sup.-8
0.69 3.21 .times. 10.sup.-3 0.66 4.58 .times. 10.sup.-9 T 0.85 3.32
.times. 10.sup.-3 6.08 .times. 10.sup.-10 rs10737692 194280590 A
0.148 0.65 1.40 .times. 10.sup.-7 0.69 3.47 .times. 10.sup.-3 0.66
6.95 .times. 10.sup.-9 G 0.88 0.017 3.51 .times. 10.sup.-9
rs12127378 194332749 C 0.155 0.66 2.84 .times. 10.sup.-7 0.70 5.84
.times. 10.sup.-3 0.67 1.83 .times. 10.sup.-8 T 0.73 4.78 .times.
10.sup.-4 4.38 .times. 10.sup.-10 rs12041661 194333325 A 0.155 0.67
3.50 .times. 10.sup.-7 0.70 6.18 .times. 10.sup.-3 0.68 2.43
.times. 10.sup.-8 C 0.72 2.81 .times. 10.sup.-4 3.50 .times.
10.sup.-10 rs10442656 194338365 T 0.156 0.67 3.58 .times. 10.sup.-7
0.82 6.16 .times. 10.sup.-3 0.74 4.69 .times. 10.sup.-8 C 0.96
0.429 1.66 .times. 10.sup.-7 rs2477070 194344416 G 0.154 0.66 1.89
.times. 10.sup.-7 0.82 6.18 .times. 10.sup.-3 0.74 2.96 .times.
10.sup.-8 A 0.74 8.00 .times. 10.sup.-4 5.56 .times. 10.sup.-10
rs1747827 194347048 T 0.155 0.67 3.60 .times. 10.sup.-7 0.81 5.87
.times. 10.sup.-3 0.74 4.45 .times. 10.sup.-8 C 0.73 5.09 .times.
10.sup.-4 5.93 .times. 10.sup.-10 rs2488411 194390456 C 0.154 0.66
1.48 .times. 10.sup.-7 0.70 6.04 .times. 10.sup.-3 0.67 1.05
.times. 10.sup.-8 T 0.95 0.398 9.34 .times. 10.sup.-8 rs1891497
194391212 A 0.154 0.66 2.03 .times. 10.sup.-7 0.70 6.39 .times.
10.sup.-3 0.67 1.41 .times. 10.sup.-8 G 0.76 1.62 .times. 10.sup.-3
1.19 .times. 10.sup.-9 rs1747815 194429760 A 0.15 0.65 8.05 .times.
10.sup.-8 0.83 0.017 0.74 5.45 .times. 10.sup.-8 G 0.53 3.14
.times. 10.sup.-7 5.04 .times. 10.sup.-13 rs1775454 194458955 T
0.146 0.65 1.96 .times. 10.sup.-7 0.90 0.057 0.77 4.15 .times.
10.sup.-6 C 0.90 0.119 1.77 .times. 10.sup.-6 rs1775456 194464712 G
0.147 0.65 8.45 .times. 10.sup.-8 0.86 0.043 0.75 2.95 .times.
10.sup.-7 A 0.53 4.27 .times. 10.sup.-7 3.71 .times. 10.sup.-12
rs1924518 194469984 A 0.149 0.65 5.81 .times. 10.sup.-8 0.73 0.071
0.66 1.08 .times. 10.sup.-8 G 0.53 8.61 .times. 10.sup.-7 2.82
.times. 10.sup.-9 rs1775444 194472347 T 0.149 0.65 5.81 .times.
10.sup.-8 0.86 0.043 0.75 2.47 .times. 10.sup.-7 C 0.53 9.43
.times. 10.sup.-7 5.53 .times. 10.sup.-12 rs12026183 194544689 T
0.131 0.62 1.06 .times. 10.sup.-8 0.86 0.025 0.73 1.31 .times.
10.sup.-7 C 0.55 3.99 .times. 10.sup.-6 5.45 .times. 10.sup.-12
rs10922300 194546342 T 0.12 0.65 1.01 .times. 10.sup.-6 0.79 3.16
.times. 10.sup.-3 0.71 .sup. 8.11 .times. 10.sup.-8 C 0.59 2.36
.times. 10.sup.-4 7.44 .times. 10.sup.-11 rs10922326 194599319 G
0.117 0.67 9.81 .times. 10.sup.-6 0.70 8.32 .times. 10.sup.-3 0.68
1.30 .times. 10.sup.-6 T 0.62 3.20 .times. 10.sup.-5 1.97 .times.
10.sup.-9 Freq: Minor allele frequencies in the CHOP discovery
cases. A1: protective allele in Caucasians; A2 risk allele in AAs.
Combined P-values from fixed-effect meta-analyses. *rs2786098 and
rs12134409 imputed in the MAGIC and MRCA cohorts. When all samples
were combined, P-values were obtained by jointly testing the SNP
and SNP by race interaction effects.
TABLE-US-00003 TABLES 3A and 3B Logistic regression at the 1q31
locus in the EA discovery and AA cohorts after conditioning on A)
rs2786098 and B) rs1775456. Table 3A Conditioning on rs2786098 SNP
Position EA P-val AA P-val rs2821106 194115942 0.521 0.013
rs12134409 194123724 0.109 0.044 rs2111931 194260875 0.101 0.021
rs10737692 194280590 0.076 0.183 rs12127378 194332749 0.445 0.056
rs12041661 194333325 0.475 0.057 rs10442656 194338365 0.507 0.430
rs2477070 194344416 0.446 0.089 rs1747827 194347048 0.482 0.078
rs2488411 194390456 0.310 0.485 rs1891497 194391212 0.359 0.157
rs1747815 194429760 0.115 5.00 .times. 10.sup.-4 rs1775454
194458955 0.250 0.671 rs1775456 194464712 0.094 2.44 .times.
10.sup.-4 rs1924518 194469984 0.124 6.04 .times. 10.sup.-4
rs1775444 194472347 0.124 8.59 .times. 10.sup.-4 rs12026183
194544689 0.034 3.05 .times. 10.sup.-3 rs10922300 194546342 0.180
0.019 rs10922326 194599319 0.166 2.26 .times. 10.sup.-3 Table 3B
Conditioning on rs1775456 SNP Position EA P-val AA P-val rs2786098
194057565 0.195 0.077 rs2821106 194115942 0.722 0.443 rs12134409
194123724 0.158 0.872 rs2111931 194260875 0.225 0.236 rs10737692
194280590 0.157 0.347 rs12127378 194332749 0.752 0.945 rs12041661
194333325 0.677 0.868 rs10442656 194338365 0.689 0.279 rs2477070
194344416 0.746 0.661 rs1747827 194347048 0.674 0.708 rs2488411
194390456 0.943 0.301 rs1891497 194391212 0.887 0.428 rs1747815
194429760 0.399 0.922 rs1775454 194458955 0.679 0.710 rs12026183
194544689 0.116 0.897 rs10922300 194546342 0.290 0.539 rs10922326
194599319 0.348 0.314
TABLE-US-00004 TABLE 4 Genotyping quality control values for the
individual sample sets. Low Low SNP Genotyping Genotyping call HWE
(<98%) (<98%) rates < MAF < P < Sample Case Control
95% 1% 10.sup.-5 GIF Discovery 42 132 8557 22087 2110 1.06 COPSAC 5
14 8508 24121 526 1.03 MAGIC 15 62 8357 1910 550 1.04 MRCA 11 56
7436 215 541 1.01 AA 14 43 8707 5645 4032 1.13
TABLE-US-00005 TABLE 5 Call rates and Hardy Weinberg P-values for
the asthma associated SNPs in the discovery cohort. Percent Missing
O(HET)- E(HET)- P- O(HET)- E(HET)- P- O(HET)- E(HET)- P- SNP
genotype Control Control Control All All All Case Case Case
rs2786098 0.006 0.324 0.342 0.022 0.309 0.320 0.074 0.271 0.258
0.179 rs2821106 0.002 0.223 0.229 0.185 0.212 0.213 0.795 0.184
0.169 0.006 rs12134409 0.008 0.328 0.341 0.096 0.312 0.319 0.203
0.270 0.259 0.283 rs2111931 0.003 0.323 0.329 0.323 0.307 0.309
0.766 0.269 0.252 0.054 rs10737692 0.002 0.323 0.329 0.390 0.307
0.309 0.766 0.268 0.253 0.099 rs12127378 0.010 0.330 0.337 0.363
0.316 0.317 0.815 0.279 0.262 0.064 rs12041661 0.007 0.330 0.335
0.475 0.316 0.316 1 0.280 0.263 0.064 rs10442656 0.002 0.333 0.338
0.479 0.318 0.319 0.954 0.282 0.264 0.065 rs2477070 0.003 0.332
0.338 0.440 0.317 0.318 0.908 0.279 0.263 0.065 rs1747827 0.008
0.331 0.337 0.476 0.317 0.317 1 0.281 0.264 0.065 rs2488411 0.005
0.333 0.338 0.441 0.318 0.318 0.908 0.279 0.262 0.065 rs1891497
0.013 0.330 0.336 0.398 0.315 0.316 0.815 0.277 0.261 0.083
rs1747815 0.005 0.326 0.332 0.432 0.311 0.312 0.813 0.270 0.256
0.135 rs1775454 0.010 0.316 0.324 0.225 0.303 0.305 0.628 0.269
0.252 0.053 rs1775456 0.012 0.319 0.329 0.163 0.303 0.309 0.338
0.263 0.251 0.212 rs1924518 0.001 0.325 0.331 0.431 0.309 0.311
0.768 0.269 0.256 0.135 rs1775444 0.002 0.326 0.332 0.395 0.309
0.312 0.723 0.267 0.254 0.171 rs12026183 0.003 0.305 0.311 0.364
0.285 0.289 0.373 0.232 0.229 0.763 rs10922300 0.004 0.274 0.286
0.068 0.258 0.266 0.096 0.216 0.213 0.871 rs10922326 0.001 0.265
0.271 0.297 0.248 0.254 0.193 0.206 0.209 0.621 O(HET) observed
heterozygosity; E(HET) expected heterozygosity.
TABLE-US-00006 TABLE 6 Imputed SNPs at the 1q31 locus. P-values and
odds ratios of the associated SNPs imputed from the HapMap phased
chromosomes in the EACHOP discovery cohort. Posterior Control Case
Missing Origin SNP Position Allele call info MAF MAF data OR
P-value Imputed rs2821125 195578785 C 0.996 0.991 0.223 0.152 0.008
0.623 7.05 .times. 10.sup.-9 Imputed rs1337168 195582862 C 0.997
0.992 0.223 0.152 0.008 0.624 7.23 .times. 10.sup.-9 Imputed
rs1337167 195583058 T 0.997 0.992 0.223 0.152 0.008 0.624 7.26
.times. 10.sup.-9 Imputed rs2786101 195587409 T 0.997 0.993 0.224
0.152 0.006 0.623 7.61 .times. 10.sup.-9 Genotyped rs2786098
195592531 T 0.997 1.000 0.222 0.152 0.003 0.629 7.30 .times.
10.sup.-9 Imputed rs2821116 195595664 A 0.998 0.995 0.224 0.153
0.006 0.627 8.17 .times. 10.sup.-9 Imputed rs2786119 195596158 A
0.998 0.995 0.224 0.153 0.006 0.627 8.19 .times. 10.sup.-9 Imputed
rs2786117 195598780 A 0.998 0.995 0.224 0.153 0.006 0.627 8.19
.times. 10.sup.-9 Imputed rs10801603 195604453 G 0.998 0.994 0.224
0.153 0.006 0.627 8.49 .times. 10.sup.-9 Imputed rs2821107
195610573 T 0.996 0.991 0.224 0.153 0.013 0.627 1.44 .times.
10.sup.-8 Imputed rs2759656 195619592 A 0.996 0.990 0.224 0.154
0.015 0.627 1.43 .times. 10.sup.-8 Imputed rs2821103 195621187 A
0.988 0.953 0.132 0.092 0.037 0.664 2.22 .times. 10.sup.-5 Imputed
rs2759661 195629931 G 0.998 0.996 0.223 0.156 0.007 0.642 1.29
.times. 10.sup.-8 Imputed rs2476019 195632766 C 0.998 0.996 0.223
0.156 0.007 0.642 1.29 .times. 10.sup.-8 Imputed rs2821132
195646465 T 0.998 0.996 0.223 0.155 0.006 0.640 1.33 .times.
10.sup.-8 Genotyped rs2821106 195650908 T 1.000 1.000 0.134 0.094
0.000 0.668 3.62 .times. 10.sup.-5 Genotyped rs12134409 195658690 T
0.993 1.000 0.220 0.153 0.007 0.643 3.55 .times. 10.sup.-8 Imputed
rs17554990 195662731 A 0.998 0.996 0.223 0.155 0.006 0.641 1.43
.times. 10.sup.-8 Imputed rs6685222 195675283 T 0.998 0.996 0.223
0.155 0.006 0.641 1.43 .times. 10.sup.-8 Imputed rs17555558
195679789 A 0.937 0.870 0.257 0.177 0.214 0.622 6.28 .times.
10.sup.-8 Imputed rs10922234 195702662 G 0.996 0.991 0.214 0.152
0.011 0.658 7.47 .times. 10.sup.-8 Imputed rs12023045 195718785 G
0.996 0.991 0.214 0.152 0.012 0.658 8.04 .times. 10.sup.-8 Imputed
rs12563307 195719826 A 0.995 0.990 0.214 0.152 0.014 0.661 8.06
.times. 10.sup.-8 Imputed rs12133659 195741277 A 0.995 0.983 0.133
0.094 0.015 0.677 5.49 .times. 10.sup.-5 Imputed rs12132165
195744908 A 0.995 0.984 0.134 0.095 0.013 0.679 5.69 .times.
10.sup.-5 Imputed rs4915550 195774888 A 0.998 0.995 0.210 0.147
0.007 0.647 4.82 .times. 10.sup.-8 Genotyped rs4915551 195775524 G
1.000 1.000 0.231 0.179 0.000 0.729 3.12 .times. 10.sup.-5 Imputed
rs4915552 195779401 A 1.000 0.999 0.210 0.148 0.001 0.653 1.25
.times. 10.sup.-7 Imputed rs10754224 195779412 A 1.000 0.999 0.210
0.148 0.001 0.653 1.25 .times. 10.sup.-7 Imputed rs4316386
195782400 A 1.000 0.999 0.210 0.148 0.001 0.653 1.25 .times.
10.sup.-7 Imputed rs10922251 195788433 G 0.996 0.988 0.204 0.144
0.011 0.656 9.60 .times. 10.sup.-8 Imputed rs6677361 195788500 T
0.996 0.988 0.204 0.144 0.011 0.656 9.60 .times. 10.sup.-8 Imputed
rs12028758 195789581 T 1.000 0.999 0.210 0.148 0.001 0.653 1.25
.times. 10.sup.-7 Imputed rs10922253 195794238 G 0.981 0.955 0.230
0.161 0.059 0.641 2.92 .times. 10.sup.-7 Imputed rs10494758
195794772 G 1.000 0.999 0.210 0.148 0.001 0.653 1.25 .times.
10.sup.-7 Genotyped rs2111931 195795841 C 1.000 1.000 0.209 0.148
0.000 0.653 1.16 .times. 10.sup.-7 Imputed rs1421397 195800977 T
1.000 0.999 0.210 0.148 0.001 0.653 1.26 .times. 10.sup.-7 Imputed
rs6689216 195802848 A 1.000 0.999 0.210 0.148 0.001 0.653 1.25
.times. 10.sup.-7 Imputed rs10922255 195803652 C 1.000 0.999 0.210
0.148 0.001 0.653 1.25 .times. 10.sup.-7 Imputed rs10922256
195811930 T 1.000 0.999 0.210 0.148 0.001 0.653 1.25 .times.
10.sup.-7 Imputed rs10922257 195812343 A 1.000 0.999 0.210 0.148
0.001 0.653 1.25 .times. 10.sup.-7 Imputed rs6676073 195813049 T
1.000 0.999 0.210 0.148 0.001 0.653 1.25 .times. 10.sup.-7
Genotyped rs10737692 195815556 A 1.000 1.000 0.210 0.149 0.000
0.658 1.84 .times. 10.sup.-7 Imputed rs4915555 195818137 G 1.000
0.999 0.210 0.148 0.001 0.653 1.26 .times. 10.sup.-7 Imputed
rs12131160 195822142 C 1.000 0.999 0.210 0.148 0.001 0.653 1.26
.times. 10.sup.-7 Imputed rs2193734 195824175 G 1.000 0.999 0.210
0.148 0.001 0.653 1.26 .times. 10.sup.-7 Imputed rs8179369
195828030 T 1.000 0.999 0.210 0.148 0.001 0.653 1.26 .times.
10.sup.-7 Imputed rs12747786 195832455 C 1.000 0.999 0.210 0.148
0.001 0.653 1.26 .times. 10.sup.-7 Imputed rs6428411 195836280 A
0.987 0.971 0.185 0.132 0.038 0.670 8.38 .times. 10.sup.-7 Imputed
rs6428412 195836641 A 0.933 0.852 0.198 0.147 0.208 0.702 1.09
.times. 10.sup.-7 Imputed rs1833464 195838200 G 0.998 0.997 0.209
0.147 0.004 0.653 1.13 .times. 10.sup.-7 Imputed rs1362939
195846707 C 1.000 1.000 0.216 0.156 0.000 0.670 3.61 .times.
10.sup.-7 Imputed rs12116508 195847075 C 1.000 1.000 0.216 0.156
0.000 0.670 3.61 .times. 10.sup.-7 Imputed rs4915557 195849224 G
1.000 1.000 0.216 0.156 0.000 0.670 3.61 .times. 10.sup.-7 Imputed
rs4915558 195849432 T 1.000 1.000 0.216 0.156 0.000 0.670 3.61
.times. 10.sup.-7 Imputed rs3814321 195850466 T 1.000 1.000 0.216
0.156 0.000 0.670 3.61 .times. 10.sup.-7 Imputed rs12133885
195859191 T 1.000 1.000 0.216 0.156 0.000 0.670 3.61 .times.
10.sup.-7 Genotyped rs12127378 195867715 C 0.995 1.000 0.215 0.155
0.005 0.669 3.65 .times. 10.sup.-7 Genotyped rs12041661 195868291 A
0.996 1.000 0.215 0.156 0.004 0.672 4.50 .times. 10.sup.-7
Genotyped rs10442656 195873331 T 1.000 1.000 0.217 0.157 0.000
0.673 4.58 .times. 10.sup.-7 Genotyped rs2477070 195879382 G 1.000
1.000 0.216 0.155 0.000 0.666 2.44 .times. 10.sup.-7 Genotyped
rs1747827 195882014 T 0.998 1.000 0.216 0.156 0.002 0.672 4.61
.times. 10.sup.-7 Imputed rs1775453 195895965 C 0.995 0.988 0.240
0.177 0.011 0.678 5.43 .times. 10.sup.-7 Imputed rs2488409
195911204 T 0.997 0.992 0.213 0.154 0.005 0.676 4.11 .times.
10.sup.-7 Imputed rs2488410 195917128 A 1.000 1.000 0.216 0.155
0.000 0.668 2.86 .times. 10.sup.-7 Imputed rs1775450 195919225 T
1.000 1.000 0.216 0.155 0.000 0.668 2.82 .times. 10.sup.-7 Imputed
rs1747811 195919659 T 1.000 1.000 0.216 0.155 0.000 0.668 2.81
.times. 10.sup.-7 Imputed rs1578720 195923772 G 1.000 1.000 0.216
0.155 0.000 0.667 2.75 .times. 10.sup.-7 Genotyped rs2488411
195925422 C 0.999 1.000 0.217 0.155 0.001 0.663 1.91 .times.
10.sup.-7 Genotyped rs1891497 195926178 A 0.994 1.000 0.215 0.155
0.006 0.666 2.91 .times. 10.sup.-7 Imputed rs2358774 195931018 G
1.000 1.000 0.216 0.155 0.000 0.667 2.72 .times. 10.sup.-7 Imputed
rs1573098 195950430 G 1.000 1.000 0.216 0.155 0.000 0.667 2.72
.times. 10.sup.-7 Imputed rs1621898 195951122 T 1.000 1.000 0.216
0.155 0.000 0.667 2.72 .times. 10.sup.-7 Imputed rs1775457
195951774 C 1.000 1.000 0.216 0.155 0.000 0.667 2.73 .times.
10.sup.-7 Imputed rs2147300 195959750 G 0.999 0.998 0.216 0.154
0.005 0.661 2.20 .times. 10.sup.-7 Imputed rs2488387 195960660 A
0.975 0.944 0.227 0.162 0.084 0.660 1.99 .times. 10.sup.-7
Genotyped rs1747815 195964726 T 1.000 1.000 0.213 0.151 0.000 0.656
1.19 .times. 10.sup.-7 Imputed rs1747814 195966322 C 0.936 0.863
0.200 0.138 0.184 0.643 3.36 .times. 10.sup.-8 Imputed rs2488400
195968848 G 1.000 0.999 0.213 0.151 0.001 0.656 1.15 .times.
10.sup.-7 Imputed rs1747817 195978115 C 0.988 0.974 0.227 0.161
0.035 0.652 7.08 .times. 10.sup.-8 Imputed rs1775441 195978291 T
0.988 0.974 0.227 0.161 0.035 0.652 7.05 .times. 10.sup.-8 Imputed
rs1775442 195979023 A 0.988 0.974 0.227 0.161 0.035 0.652 7.08
.times. 10.sup.-8 Genotyped rs1775454 195993921 T 0.996 1.000 0.206
0.146 0.004 0.660 2.92 .times. 10.sup.-7 Genotyped rs1775456
195999678 G 0.991 1.000 0.209 0.147 0.009 0.653 1.40 .times.
10.sup.-7 Imputed rs1342696 196000076 G 1.000 1.000 0.212 0.149
0.000 0.652 8.63 .times. 10.sup.-8 Imputed rs1539413 196000565 C
1.000 1.000 0.212 0.149 0.000 0.652 8.63 .times. 10.sup.-8 Imputed
rs2488394 196002120 C 1.000 1.000 0.212 0.149 0.000 0.652 8.63
.times. 10.sup.-8 Genotyped rs1924518 196004950 A 1.000 1.000 0.212
0.149 0.000 0.652 8.63 .times. 10.sup.-8 Imputed rs2488395
196005403 T 1.000 1.000 0.212 0.149 0.000 0.652 8.63 .times.
10.sup.-8 Genotyped rs1775444 196007313 T 1.000 1.000 0.212 0.149
0.000 0.652 8.63 .times. 10.sup.-8 Imputed rs2488396 196008794 C
1.000 1.000 0.212 0.149 0.000 0.652 8.75 .times. 10.sup.-8 Imputed
rs1342694 196016491 C 1.000 1.000 0.212 0.149 0.001 0.653 8.82
.times. 10.sup.-8 Imputed rs2477069 196018105 A 1.000 1.000 0.212
0.149 0.001 0.653 8.88 .times. 10.sup.-8 Imputed rs1775469
196019697 A 1.000 1.000 0.212 0.149 0.001 0.653 8.88 .times.
10.sup.-8 Imputed rs1747825 196019759 C 1.000 1.000 0.212 0.149
0.001 0.653 8.88 .times. 10.sup.-8 Imputed rs1775468 196020687 C
1.000 1.000 0.212 0.149 0.001 0.653 8.88 .times. 10.sup.-8 Imputed
rs1775467 196021570 A 1.000 1.000 0.212 0.149 0.001 0.653 8.88
.times. 10.sup.-8 Imputed rs1775466 196021590 A 1.000 1.000 0.212
0.149 0.001 0.653 8.88 .times. 10.sup.-8 Imputed rs1775465
196021966 G 1.000 1.000 0.212 0.149 0.001 0.653 8.82 .times.
10.sup.-8 Imputed rs1775464 196021987 T 1.000 1.000 0.212 0.149
0.001 0.653 8.82 .times. 10.sup.-8 Imputed rs1747823 196022269 C
1.000 1.000 0.212 0.149 0.001 0.653 8.88 .times. 10.sup.-8 Imputed
rs2454640 196032627 T 1.000 1.000 0.212 0.149 0.001 0.653 8.82
.times. 10.sup.-8 Imputed rs1499593 196035130 C 1.000 1.000 0.212
0.149 0.001 0.653 8.82 .times. 10.sup.-8 Imputed rs10922288
196036163 C 1.000 1.000 0.212 0.149 0.001 0.653 8.82 .times.
10.sup.-8 Imputed rs12740849 196036444 T 0.912 0.777 0.107 0.083
0.253 0.754 1.95 .times. 10.sup.-5 Imputed rs2133536 196040910 T
1.000 1.000 0.212 0.149 0.001 0.653 8.82 .times. 10.sup.-8 Imputed
rs12125742 196047367 C 1.000 1.000 0.212 0.149 0.001 0.653 8.82
.times. 10.sup.-8 Imputed rs4915566 196049359 C 1.000 1.000 0.212
0.149 0.001 0.653 8.82 .times. 10.sup.-8 Imputed rs6428417
196054342 C 1.000 1.000 0.212 0.149 0.001 0.653 8.82 .times.
10.sup.-8 Imputed rs10922294 196057566 A 1.000 1.000 0.212 0.149
0.001 0.653 8.82 .times. 10.sup.-8 Imputed rs6697696 196058878 G
1.000 1.000 0.212 0.149 0.001 0.653 8.82 .times. 10.sup.-8 Imputed
rs6704186 196060310 C 1.000 1.000 0.212 0.149 0.001 0.653 8.82
.times. 10.sup.-8 Imputed rs4915569 196061641 C 1.000 1.000 0.212
0.149 0.001 0.653 8.81 .times. 10.sup.-8 Imputed rs12140293
196076702 A 0.999 0.998 0.196 0.132 0.001 0.621 2.17 .times.
10.sup.-8 Imputed rs12118454 196077272 T 0.979 0.945 0.164 0.117
0.063 0.677 1.74 .times. 10.sup.-7 Genotyped rs12026183 196079655 T
1.000 1.000 0.196 0.131 0.000 0.618 1.10 .times. 10.sup.-8
Genotyped rs10922300 196081308 T 0.999 1.000 0.174 0.121 0.001
0.654 1.35 .times. 10.sup.-6 Imputed rs10801625 196081382 A 0.999
0.997 0.206 0.141 0.003 0.636 2.92 .times. 10.sup.-8 Imputed
rs10922304 196087568 A 0.996 0.989 0.201 0.142 0.015 0.657 3.89
.times. 10.sup.-8 Imputed rs10922305 196088392 C 0.998 0.995 0.206
0.142 0.006 0.639 2.30 .times. 10.sup.-8 Genotyped rs1499602
196109827 C 0.999 1.000 0.398 0.341 0.001 0.783 9.58
.times. 10.sup.-5 Genotyped rs10801629 196110990 T 1.000 1.000
0.427 0.369 0.000 0.783 7.54 .times. 10.sup.-5 Imputed rs10801632
196122786 A 0.997 0.996 0.398 0.341 0.008 0.783 8.92 .times.
10.sup.-5 Imputed rs9662705 196130037 T 0.998 0.997 0.398 0.341
0.006 0.784 9.77 .times. 10.sup.-5 Genotyped rs10922326 196134285 G
1.000 1.000 0.165 0.119 0.000 0.683 1.70 .times. 10.sup.-5
TABLE-US-00007 TABLE 7 Comparative association at the 1q31 locus
inthe Caucasian cohorts; the Replication cohort (Rep) consisted of
the Danish (COPSAC), German (MAGIC/ISAAC) and British (MRCA)
cohorts compared to the discovery cohort (Disc). Disc case Disc
control Rep case Rep control SNP Pos A1 MAF MAF Disc P Disc OR MAF
MAF rs2786098 194057565 A 0.152 0.222 8.55 .times. 10.sup.-9 0.629
0.183 0.225 rs2821106 194115942 A 0.0927 0.134 2.06 .times.
10.sup.-5 0.658 0.113 0.136 rs12134409 194123724 T 0.153 0.220 2.72
.times. 10.sup.-8 0.639 0.186 0.229 rs2111931 194260875 C 0.147
0.210 8.71 .times. 10.sup.-8 0.649 0.175 0.209 rs10737692 194280590
A 0.148 0.210 1.40 .times. 10.sup.-7 0.654 0.176 0.209 rs12127378
194332749 C 0.155 0.216 2.84 .times. 10.sup.-7 0.665 0.182 0.215
rs12041661 194333325 A 0.155 0.215 3.50 .times. 10.sup.-7 0.668
0.182 0.214 rs10442656 194338365 T 0.156 0.217 3.58 .times.
10.sup.-7 0.670 0.182 0.214 rs2477070 194344416 G 0.154 0.216 1.89
.times. 10.sup.-7 0.662 0.182 0.214 rs1747827 194347048 T 0.155
0.216 3.60 .times. 10.sup.-7 0.668 0.182 0.215 rs2488411 194390456
C 0.154 0.217 1.48 .times. 10.sup.-7 0.659 0.182 0.214 rs1891497
194391212 A 0.154 0.216 2.03 .times. 10.sup.-7 0.661 0.182 0.214
rs1747815 194429760 A 0.150 0.213 8.05 .times. 10.sup.-8 0.651
0.180 0.209 rs1775454 194458955 T 0.146 0.207 1.96 .times.
10.sup.-7 0.655 0.165 0.181 rs1775456 194464712 G 0.147 0.210 8.45
.times. 10.sup.-8 0.647 0.179 0.203 rs1924518 194469984 A 0.149
0.213 5.81 .times. 10.sup.-8 0.647 0.192 0.217 rs1775444 194472347
T 0.149 0.213 5.81 .times. 10.sup.-8 0.647 0.179 0.203 rs12026183
194544689 T 0.131 0.197 1.06 .times. 10.sup.-8 0.616 0.161 0.181
rs10922300 194546342 T 0.120 0.174 1.01 .times. 10.sup.-6 0.649
0.135 0.166 rs10922326 194599319 G 0.117 0.165 9.81 .times.
10.sup.-6 0.674 0.127 0.148 Fisher's Fixed Fixed effect SNP Rep P
Rep OR combined P effect P OR (95% CI) rs2786098 6.47 .times.
10.sup.-4 0.773 .sup. 3.91 .times. 10.sup.-11 .sup. 9.33 .times.
10.sup.-11 0.702 (0.630-0.781 rs2821106 1.81 .times. 10.sup.-3
0.814 1.81 .times. 10.sup.-7 .sup. 6.32 .times. 10.sup.-06 0.734
(0.642-0.839) rs12134409 5.37 .times. 10.sup.-4 0.771 .sup. 9.98
.times. 10.sup.-11 .sup. 1.64 .times. 10.sup.-10 0.707
(0.636-0.786) rs2111931 3.21 .times. 10.sup.-3 0.691 1.70 .times.
10.sup.-9 4.58 .times. 10.sup.-9 0.658 (0.572-0.757) rs10737692
3.47 .times. 10.sup.-3 0.691 2.90 .times. 10.sup.-9 6.95 .times.
10.sup.-9 0.662 (0.576-0.761) rs12127378 5.84 .times. 10.sup.-3
0.704 9.37 .times. 10.sup.-9 1.83 .times. 10.sup.-8 0.674
(0.587-0.773) rs12041661 6.18 .times. 10.sup.-3 0.705 1.21 .times.
10.sup.-8 2.43 .times. 10.sup.-8 0.676 (0.589-0.776) rs10442656
6.16 .times. 10.sup.-3 0.816 1.23 .times. 10.sup.-8 4.69 .times.
10.sup.-8 0.743 (0.668-0.827) rs2477070 6.18 .times. 10.sup.-3
0.816 6.70 .times. 10.sup.-9 2.96 .times. 10.sup.-8 0.739
(0.665-0.823) rs1747827 5.87 .times. 10.sup.-3 0.815 1.18 .times.
10.sup.-8 4.45 .times. 10.sup.-8 0.743 (0.667-0.826) rs2488411 6.04
.times. 10.sup.-3 0.704 5.19 .times. 10.sup.-9 1.05 .times.
10.sup.-8 0.669 (0.583-0.768) rs1891497 6.39 .times. 10.sup.-3
0.705 7.40 .times. 10.sup.-9 1.41 .times. 10.sup.-8 0.671
(0.584-0.770) rs1747815 0.017 0.832 7.63 .times. 10.sup.-9 5.45
.times. 10.sup.-8 0.742 (0.666-0.826) rs1775454 0.057 0.899 5.74
.times. 10.sup.-8 4.15 .times. 10.sup.-6 0.769 (0.688-0.860)
rs1775456 0.043 0.859 1.98 .times. 10.sup.-8 2.95 .times. 10.sup.-7
0.753 (0.676-0.839) rs1924518 0.071 0.733 2.22 .times. 10.sup.-8
1.08 .times. 10.sup.-8 0.664 (0.577-0.764) rs1775444 0.043 0.860
1.40 .times. 10.sup.-8 2.47 .times. 10.sup.-7 0.753 (0.676-0.838)
rs12026183 0.025 0.863 1.59 .times. 10.sup.-9 1.31 .times.
10.sup.-7 0.735 (0.656-0.824) rs10922300 3.16 .times. 10.sup.-3
0.789 1.75 .times. 10.sup.-8 8.11 .times. 10.sup.-8 0.715
(0.632-0.808) rs10922326 8.32 .times. 10.sup.-3 0.704 3.82 .times.
10.sup.-7 1.30 .times. 10.sup.-6 0.679 (0.581-0.795) A1 minor
allele. SNPs rs2786098 and rs12134409 were imputed in the MAGIC and
MRCA cohorts. Combined P-values are given for both Fisher's method
and a fixed-effect meta-analysis.
TABLE-US-00008 TABLE 8 Cochrane test for heterogeneity P-values for
the fixed effect meta-analysis presented in Table 7 SNP Cochrane
test for heterogeneity P-value rs2786098 0.059 rs2821106 0.122
rs12134409 0.085 rs2111931 0.712 rs10737692 0.746 rs12127378 0.737
rs12041661 0.752 rs10442656 0.069 rs2477070 0.055 rs1747827 0.068
rs2488411 0.697 rs1891497 0.704 rs1747815 0.026 rs1775454 0.06
rs1775456 0.010 rs1924518 0.480 rs1775444 0.009 rs12026183 0.004
rs10922300 0.117 rs10922326 0.824
TABLE-US-00009 TABLE 9 Individual P-values and ORs for the
individual cohorts in the combined replication set. COPSAC COPSAC
MAGIC MAGIC MRCA MRCA rs ID P-value OR P-value OR P-value OR
rs2786098 0.022 0.722 0.002 0.726 0.824 0.999 rs2821106 0.091 0.765
0.001 0.660 0.514 0.892 rs12134409 0.000 0.574 0.016 0.771 0.572
0.919 rs2111931 0.020 0.721 0.074 0.829 0.421 0.882 rs10737692
0.017 0.716 0.074 0.829 0.421 0.882 rs12127378 0.013 0.705 0.124
0.854 0.783 0.959 rs12041661 0.014 0.710 0.117 0.851 0.783 0.959
rs10442656 0.014 0.711 0.107 0.847 0.758 0.954 rs2477070 0.014
0.710 0.117 0.851 0.783 0.959 rs1747827 0.014 0.710 0.100 0.844
0.783 0.959 rs2488411 0.020 0.724 0.118 0.852 0.785 0.960 rs1891497
0.029 0.737 0.072 0.830 0.792 0.961 rs1747815 0.024 0.729 0.143
0.859 0.810 0.964 rs1775454 0.061 0.764 0.304 0.956 0.996 0.963
rs1775456 0.039 0.747 0.333 0.905 0.943 0.989 rs1924518 0.039 0.747
0.505 0.929 0.971 0.987 rs1775444 0.039 0.747 0.321 0.903 0.929
0.987 rs12026183 0.007 0.675 0.545 0.971 0.492 0.898 rs10922300
0.005 0.665 0.057 0.761 0.453 0.904 rs10922326 0.017 0.689 0.379
0.955 0.461 0.809
TABLE-US-00010 TABLE 10 Odds ratios and P-values for the combined
analysis of all European ancestry asthma samples Chr Rsid pos
allele_A allele_B all_OR frequentist_add_proper 1 rs2821125
195578785 C G 1.419 3.03E-09 1 rs1337168 195582862 C G 1.419
3.05E-09 1 rs1337167 195583058 C T 0.705 3.09E-09 1 rs2786101
195587409 A T 0.705 3.06E-09 1 rs2786098 195592531 G T 0.705
3.04E-09 1 rs2821116 195595664 A T 1.419 2.99E-09 1 rs2786119
195596158 A C 1.419 2.98E-09 1 rs2786117 195598780 A G 1.419
3.01E-09 1 rs2786116 195600402 A G 0.705 3.09E-09 1 rs10801603
195604453 A G 0.705 2.96E-09 1 rs2821107 195610573 A T 0.720
4.61E-09 1 rs2759656 195619592 A G 1.388 4.66E-09 1 rs2821103
195621187 A G 1.398 6.31E-07 17 rs1008723 35319793 G T 0.795
9.05E-08 17 rs10445308 35191573 C T 0.806 3.84E-07 17 rs1054609
35286803 A C 0.798 1.74E-07 17 rs10852936 35285240 C T 0.798
1.73E-07 17 rs11078925 35278734 C T 1.255 1.71E-07 17 rs11078926
35316502 A G 1.274 2.60E-08 17 rs11078927 35317931 C T 0.783
2.36E-08 17 rs11557466 35278152 C T 0.797 1.71E-07 17 rs11557467
35282160 G T 0.806 8.21E-07 17 rs11870965 35283731 A T 1.254
1.72E-07 17 rs12150079 35278943 A G 1.241 5.59E-05 17 rs12232497
35293645 C T 1.254 1.77E-07 17 rs12936231 35282646 C G 0.806
7.18E-07 17 rs12950743 35302759 C T 1.236 7.54E-07 17 rs2290400
35319766 C T 1.274 3.22E-08 17 rs2305479 35315743 C T 0.798
1.21E-07 17 rs2305480 35315722 A G 1.278 3.31E-08 17 rs2872507
35294289 A G 1.254 1.77E-07 17 rs3816470 35239327 A G 0.826
6.61E-06 17 rs4795397 35277271 A G 0.797 1.71E-07 17 rs4795400
35320546 C T 0.783 2.08E-08 17 rs7359623 35303115 C T 0.835
2.55E-06 17 rs8067378 35304874 A G 0.803 5.27E-07 17 rs8069176
35310723 A G 1.275 5.84E-08 17 rs869402 35321569 C T 0.795 9.07E-08
17 rs907091 35175268 C T 1.234 1.71E-06 17 rs907092 35175785 A G
1.239 1.06E-06 17 rs9303277 35229995 C T 0.803 4.97E-07 17
rs9901146 35296869 A G 1.236 7.44E-07 17 rs9907088 35288642 A G
1.254 1.75E-07 17 rs7216389 35323475 C T 1.254 2.41E-07 17
rs9303280 35327557 C T 0.800 2.84E-07 17 rs9303281 35327572 A G
0.798 2.35E-07 17 rs7219923 35328044 C T 1.254 2.37E-07 17
rs7224129 35328952 A G 0.797 2.41E-07 17 rs4378650 35334391 A G
1.246 3.49E-07 17 rs8076131 35334438 A G 0.789 6.25E-08 17
rs12603332 35336333 C T 0.805 7.11E-07 17 rs4795405 35341943 C T
0.791 1.45E-07 17 rs4794820 35342870 A G 1.251 2.22E-07 17
rs7207600 35345186 A G 0.792 8.00E-07 17 rs8079416 35346239 C T
0.808 1.19E-06 17 rs6503525 35348700 C G 0.807 1.04E-06 17
rs8065126 35352561 C T 0.790 8.45E-07 17 rs4065985 35355458 C G
0.780 5.25E-07 17 rs4795408 35361153 A G 0.803 9.89E-07 17
rs9895948 35361889 C T 0.799 1.36E-06 17 rs17609240 35364215 G T
0.792 8.56E-07 17 rs8076474 35364760 C G 0.799 1.46E-06 17
rs1007654 35364880 A G 1.248 1.24E-06 17 rs1007655 35364945 A G
0.799 1.46E-06 17 rs2313640 35365371 C T 1.256 9.88E-07 17
rs7218742 35367887 A G 1.259 8.69E-07 17 rs7218321 35367995 C T
1.273 6.99E-07 17 rs7219080 35368042 A C 1.278 6.80E-07 17
rs6503526 35368124 C T 1.243 1.02E-06 17 rs6503527 35368245 A G
0.782 5.36E-07 17 rs3902025 35372780 G T 1.275 5.80E-08 17
rs3894194 35375519 A G 0.820 6.15E-06 17 rs7212938 35376206 G T
0.802 1.63E-06 6 rs1033700 165960069 C T 1.312 1.78E-05 6 rs2983510
165963067 A G 0.768 7.87E-05 6 rs753759 165966401 C G 0.758
1.40E-05 6 rs3008042 165970952 C T 1.331 9.47E-06 6 rs2983515
165971234 A C 0.754 1.56E-05 6 rs1358786 165974912 A G 1.473
8.35E-08 6 rs9348025 165976454 A C 0.761 2.01E-05 3 rs275358
81551603 A C 0.813 3.68E-06 3 rs276114 81560744 A T 0.854 2.23E-04
3 rs276117 81564719 A G 1.170 2.66E-04 3 rs276119 81566114 C G
1.161 1.67E-03 3 rs276123 81568696 A T 0.851 2.08E-04 3 rs276125
81571248 C T 1.175 2.03E-04 3 rs1675838 81575713 G T 0.857 3.62E-04
3 rs9843238 81577304 C T 1.161 1.63E-03 3 rs1677057 81577740 C T
1.162 1.65E-03 3 rs9309871 81579031 A C 0.800 3.62E-03 3 rs1461614
81580181 C T 0.800 3.80E-07 3 rs2372904 81581427 A G 0.834 8.17E-05
9 rs677302 9587252 C T 0.822 2.08E-06 9 rs677243 9587302 C G 1.229
1.17E-06 9 rs1412398 9589213 C T 1.236 1.40E-06 9 rs651116 9589450
G T 0.815 8.65E-07 9 rs664869 9590239 G T 0.818 9.56E-07 9
rs9407436 9590720 A C 0.810 1.47E-06 9 rs7046780 9592389 G T 1.240
9.44E-07 9 rs1326772 9592686 A C 0.806 8.29E-07 9 rs1326773 9592730
C G 1.240 9.52E-07 9 rs10977865 9593122 A T 0.807 1.05E-06
TABLE-US-00011 TABLE 11 Associated SNP P-values and odds ratios in
the North American European ancestry discovery cohort and the
African American (AA) samples. Disc Disc AA AA EA/AA case control
Disc case control AA AA Meta- SNP bp A1 MAF MAF DiscP OR A2 AAF AAF
P OR analysis rs2786098 194057565 A 0.152 0.222 8.55 .times.
10.sup.-9 0.6293 C 0.902 0.928 3.77 .times. 10.sup.-5 0.71 .sup.
5.50 .times. 10.sup.-12 rs2821106 194115942 A 0.0927 0.134 2.06
.times. 10.sup.-5 0.6581 G 0.974 0.987 3.52 .times. 10.sup.-5 0.49
1.50 .times. 10.sup.-8 rs12134409 194123724 T 0.153 0.220 2.72
.times. 10.sup.-8 0.6392 C 0.936 0.957 3.80 .times. 10.sup.-5 0.66
.sup. 2.10 .times. 10.sup.-11 rs2111931 194260875 C 0.147 0.210
8.71 .times. 10.sup.-8 0.6488 T 0.775 0.803 3.32 .times. 10.sup.-3
0.85 4.38 .times. 10.sup.-9 rs10737692 194280590 A 0.148 0.210 1.40
.times. 10.sup.-7 0.6539 G 0.685 0.711 0.017 0.88 3.12 .times.
10.sup.-8 rs12127378 194332749 C 0.155 0.216 2.84 .times. 10.sup.-7
0.6653 T 0.918 0.939 4.78 .times. 10.sup.-4 0.73 2.60 .times.
10.sup.-9 rs12041661 194333325 A 0.155 0.215 3.50 .times. 10.sup.-7
0.668 C 0.921 0.942 2.81 .times. 10.sup.-4 0.72 1.98 .times.
10.sup.-9 rs10442656 194338365 T 0.156 0.217 3.58 .times. 10.sup.-7
0.6696 C 0.767 0.775 0.429 0.96 1.05 .times. 10.sup.-6 rs2477070
194344416 G 0.154 0.216 1.89 .times. 10.sup.-7 0.662 A 0.922 0.941
8.00 .times. 10.sup.-4 0.74 2.76 .times. 10.sup.-9 rs1747827
194347048 T 0.155 0.216 3.60 .times. 10.sup.-7 0.6684 C 0.921 0.941
5.09 .times. 10.sup.-4 0.73 3.51 .times. 10.sup.-9 rs2488411
194390456 C 0.154 0.217 1.48 .times. 10.sup.-7 0.6593 T 0.769 0.777
0.398 0.95 4.01 .times. 10.sup.-7 rs1891497 194391212 A 0.154 0.216
2.03 .times. 10.sup.-7 0.6614 G 0.922 0.94 1.62 .times. 10.sup.-3
0.76 5.66 .times. 10.sup.-9 rs1747815 194429760 A 0.150 0.213 8.05
.times. 10.sup.-8 0.6508 G 0.949 0.972 3.14 .times. 10.sup.-7 0.53
.sup. 6.63 .times. 10.sup.-13 rs1775454 194458955 T 0.146 0.207
1.96 .times. 10.sup.-7 0.655 C 0.844 0.857 0.119 0.9 2.22 .times.
10.sup.-7 rs1775456 194464712 G 0.147 0.210 8.45 .times. 10.sup.-8
0.6467 A 0.95 0.973 4.27 .times. 10.sup.-7 0.53 .sup. 9.16 .times.
10.sup.-13 rs1924518 194469984 A 0.149 0.213 5.81 .times. 10.sup.-8
0.6468 G 0.951 0.973 8.61 .times. 10.sup.-7 0.53 .sup. 1.25 .times.
10.sup.-12 rs1775444 194472347 T 0.149 0.213 5.81 .times. 10.sup.-8
0.6468 C 0.951 0.973 9.43 .times. 10.sup.-7 0.53 .sup. 1.36 .times.
10.sup.-12 rs12026183 194544689 T 0.131 0.197 1.06 .times.
10.sup.-8 0.6165 C 0.951 0.972 3.99 .times. 10.sup.-6 0.55 .sup.
7.54 .times. 10.sup.-13 rs10922300 194546342 T 0.120 0.174 1.01
.times. 10.sup.-6 0.649 C 0.968 0.981 2.36 .times. 10.sup.-4 0.59
3.95 .times. 10.sup.-9 rs10922326 194599319 G 0.117 0.165 9.81
.times. 10.sup.-6 0.6736 T 0.945 0.965 3.20 .times. 10.sup.-5 0.62
6.29 .times. 10.sup.-9 A1 minor allele, A2 ancestral allele. MAF:
Minor allele frequency. AAF: ancestral allele frequency. The
reported ORs in the AA samples were calculated on the ancestral
alleles.
TABLE-US-00012 TABLE 12 Age of onset analysis in the EA discovery
cohort and AA. SNP Position EA anovaP AA anovaP rs2786098 194057565
0.058 0.086 rs2821106 194115942 0.017 0.065 rs12134409 194123724
0.324 0.061 rs2111931 194260875 0.002 0.022 rs10737692 194280590
0.016 0.015 rs12127378 194332749 0.021 0.025 rs12041661 194333325
0.025 0.078 rs10442656 194338365 0.482 0.167 rs2477070 194344416
0.012 0.105 rs1747827 194347048 0.445 0.114 rs2488411 194390456
0.094 0.237 rs1891497 194391212 0.030 0.148 rs1747815 194429760
0.274 0.124 rs1775454 194458955 0.125 0.322 rs1775456 194464712
0.027 0.166 rs1924518 194469984 0.075 0.170 rs1775444 194472347
0.024 0.121 rs12026183 194544689 0.106 0.248 rs10922300 194546342
0.084 0.316 rs10922326 194599319 0.516 0.306 P-values of ANOVA on
the log transformed ages of onset and the DENND1BSNP genotypes with
additive encoding.
REFERENCES
1. Ober C, Hoffjan S. Asthma genetics 2006: the long and winding
road to gene discovery. Genes Immun 2006; 7(2):95-100. 2. Vercelli
D. Discovering susceptibility genes for asthma and allergy. Nature
reviews 2008; 8(3):169-82. 3. Halapi E, Hakonarson H. Recent
development in genomic and proteomic research for asthma. Curr Opin
Pulm Med 2004; 10(1):22-30. 4. Martinez F D, Wright A L, Taussig L
M, Holberg C J, Halonen M, Morgan W J. Asthma and wheezing in the
first six years of life. The Group Health Medical Associates. N
Engl J Med 1995; 332(3):133-8. 5. Sears M R, Greene J M, Willan A
R, et al. A longitudinal, population-based, cohort study of
childhood asthma followed to adulthood. N Engl J Med 2003;
349(15):1414-22. 6. Moffatt M, Kabesch M, Liang L, et al. Genetic
variants regulating ORMDL3 expression contribute to the risk of
childhood asthma. Nature 2007; 448(7152):470-3. 7. Genome-wide
association study of 14,000 cases of seven common diseases and
3,000 shared controls. Nature 2007; 447(7145):661-78. 8. Kugathasan
S, Baldassano R N, Bradfield J P, et al. Loci on 20q13 and 21q22
are associated with pediatric-onset inflammatory bowel disease. Nat
Genet 2008; 40(10):1211-5. 9. Zeggini E, Scott L, Saxena R, et al.
Meta-analysis of genome-wide association data and large-scale
replication identifies additional susceptibility loci for type 2
diabetes. Nat Genet 2008; 40(5):638-45. 10. Bouzigon E, Corda E,
Aschard H, et al. Effect of 17q21 Variants and Smoking Exposure in
Early-Onset Asthma. N Engl J Med 2008. 11. Expert Panel Report 3
(EPR-3): Guidelines for the Diagnosis and Management of
Asthma-Summary Report 2007. J Allergy Clin Immunol 2007; 120(5
Suppl):S94-138. 12. Bisgaard H, Hermansen M, Buchvald F, et al.
Childhood asthma after bacterial colonization of the airway in
neonates. N Engl J Med 2007; 357(15):1487-95. 13. Bisgaard H,
Hermansen M, Loland L, Halkjaer L, Buchvald F. Intermittent inhaled
corticosteroids in infants with episodic wheezing. N Engl J Med
2006; 354(19):1998-2005. 14. Falush D, Stephens M, Pritchard J.
Inference of population structure using multilocus genotype data:
linked loci and correlated allele frequencies. Genetics 2003;
164(4):1567-87. 15. Luca D, Ringquist S, Klei L, et al. On the use
of general control samples for genome-wide association studies:
genetic matching highlights causal variants. Am J Hum Genet 2008;
82(2):453-63. 16. Gunderson K, Steemers F, Lee G, Mendoza L, Chee
M. A genome-wide scalable SNP genotyping assay using microarray
technology. Nat Genet 2005; 37(5):549-54. 17. Steemers F, Chang W,
Lee G, Barker D, Shen R, Gunderson K. Whole-genome genotyping with
the single-base extension assay. Nat Methods 2006; 3(1):31-3. 18.
Hakonarson H, Grant S, Bradfield J, et al. A genome-wide
association study identifies KIAA0350 as a type 1 diabetes gene.
Nature 2007; 448(7153):591-4. 19. J. Marchini, B. Howie, S. Myers,
G. McVean and P. Donnelly (2007) A new multipoint method for
genome-wide association studies via imputation of genotypes. Nature
Genetics 39: 906-913. 20. Lin P, Vance J, Pericak-Vance M, Martin
E. No gene is an island: the flip-flop phenomenon. Am J Hum Genet
2007; 80(3):531-8. 21. Gosens I, den Hollander A, Cremers F,
Roepman R. Composition and function of the Crumbs protein complex
in the mammalian retina. Exp Eye Res 2008. 22. den Hollander A, ten
Brink J, de Kok Y, et al. Mutations in a human homologue of
Drosophila crumbs cause retinitis pigmentosa (RP12). Nat Genet
1999; 23(2):217-21. 23. den Hollander A, Johnson K, de Kok Y, et
al. CRB1 has a cytoplasmic domain that is functionally conserved
between human and Drosophila. Hum Mol Genet 2001; 10(24):2767-73.
24. Del Villar K, Miller C. Down-regulation of DENN/MADD, a TNF
receptor binding protein, correlates with neuronal cell death in
Alzheimer's disease brain and hippocampal neurons. Proc Natl Acad
Sci USA 2004; 101(12):4210-5. 25. Miyoshi J, Takai Y. Dual role of
DENN/MADD (Rab3GEP) in neurotransmission and neuroprotection.
Trends Mol Med 2004; 10(10):476-80. 26. Lindstedt M, Lundberg K,
Borrebaeck C. Gene family clustering identifies functionally
associated subsets of human in vivo blood and tonsillar dendritic
cells. J Immunol 2005; 175(8):4839-46. 27. Su A, Cooke M, Ching K,
et al. Large-scale analysis of the human and mouse transcriptomes.
Proc Natl Acad Sci USA 2002; 99(7):4465-70. 28. Liu Y. Dendritic
cell subsets and lineages, and their functions in innate and
adaptive immunity. Cell 2001; 106(3):259-62. 29. Willinger T,
Freeman T, Hasegawa H, McMichael A, Callan M. Molecular signatures
distinguish human central memory from effector memory CD8 T cell
subsets. J Immunol 2005; 175(9):5895-903. 30. Wills-Karp M, Ewart
S. Time to draw breath: asthma-susceptibility genes are identified.
Nat Rev Genet 2004; 5(5):376-87. 31. Galanter J, Choudhry S, Eng C,
et al. ORMDL3 Gene is Associated with Asthma in Three Ethnically
Diverse Populations. Am J Respir Crit Care Med 2008. 32. Tavendale
R, Macgregor D, Mukhopadhyay S, Palmer C. A polymorphism
controlling ORMDL3 expression is associated with asthma that is
poorly controlled by current medications. J Allergy Clin Immunol
2008; 121(4):860-3. 33. Sleiman P M, Annaiah K, Imielinski M, et
al. ORMDL3 variants associated with asthma susceptibility in North
Americans of European ancestry. J Allergy Clin Immunol 2008.
EXAMPLE II
Diagnostic Methods for Asthma and Screening Assays to Identify
Therapeutic Agents Useful for the Treatment of the Same
The information herein above can be applied clinically to patients
for diagnosing an increased susceptibility for developing early
onset pediatric asthma, and therapeutic intervention. A preferred
embodiment of the invention comprises clinical application of the
information described herein to a patient. Diagnostic compositions,
including microarrays, and methods can be designed to identify the
genetic alterations described herein in nucleic acids from a
patient to assess susceptibility for developing asthma. This can
occur after a patient arrives in the clinic; the patient has blood
drawn, and using the diagnostic methods described herein, a
clinician can detect a SNP in the regions of chromosome 1 described
herein. The typical age range for a patient to be screened is
between 3 and 12 years of age. The information obtained from the
patient sample, which can optionally be amplified prior to
assessment, will be used to diagnose a patient with an increased or
decreased susceptibility for developing asthma. Kits for performing
the diagnostic method of the invention are also provided herein.
Such kits comprise a microarray comprising at least one of the SNPs
provided herein in and the necessary reagents for assessing the
patient samples as described above.
The identity of asthma-involved genes and the patient results will
indicate which variants are present, and will identify those that
possess an altered risk for developing asthma. The information
provided herein allows for therapeutic intervention at earlier
times in disease progression that previously possible. Also as
described herein above, DENND1B provides a novel target for the
development of new therapeutic agents efficacious for the treatment
of asthma.
We have observed differential induced cytokine production in NK
cell lines possessing different DENND1B alleles. See FIG. 5. YTS,
NK-92 and NKL cell lines were evaluated for their ability to
produce IFN-.gamma. after induction by a susceptible
virally-transformed target cell. NK cells were mixed with the
target cells for 18 h and then supernatants harvested and tested
for the presence of IFN-.gamma. by ELISA. Each bar represents the
mean.+-.SD of three independent experiments performed on separate
dates. The difference between the NKL and other NK cell lines was
significant p<0.01. The NKL cell line contains the DENND1B minor
allele while the YTS and NK-92 lines contain the major allele.
Natural killer cells (NK) cells are inflammatory cells that
expresses DENND1B gene at higher levels than dendritic cells. Cells
that carry the risk allele (major allele) secrete more interferon
gamma when they are activated, than do NK cells that carry the
protective (minor) allele. This implicates DENND1B in the
regulation of cytokine production/release, and that the risk allele
appears to dysregulate this process. Thus the different DENND1B
alleles in NK cells are associated with differential ability to
secrete cytokine after exposure to a standard uniform stimulus.
Accordingly, down modulation of DENN1B activity should exhibit
beneficial therapeutic affects and ameliorate asthmatic
symptoms.
In particular, it would be desirable to block expression of this
gene in those patients that are more prone to develop the disease.
In this regard, the therapeutic siRNAs described herein can be used
to block expression of the gene product based on the patient
signal, thereby inhibiting the development of the asthmatic
phenotype.
Candidate siRNA compositions for use in the invention are provided
in Table 13. Those of skill in the art can determine the sequence
of an antisense siRNA strand based on the disclosure of the sense
strand, and will appreciate the difference between any "U" and "T"
designations in the sequences which correspond to RNA and DNA
molecules, respectively. Also, methods of using known agents for
the treatment of asthma, e.g, glucocorticoids, are also provided.
In addition, shRNA constructs can be designed based on the sense
sequence provided in Table 13, and may be effective to inhibit
DENND1B expression. The shRNA constructs utilizing the sense strand
from Table 13 for the respective targets would include a hairpin
loop 3' to the sense sequence (e.g., suitable hairpins include, but
are not limited to: TCAAGAG, TTCAAGAGA, GAAGCTTG, and TTCG)
followed by the corresponding antisense sequence from the sense
strand provided in Table 13.
TABLE-US-00013 TABLE 13 Candidate DENND1B siRNA Molecules (sense)
TGACAGACATTGAAAGTAAtt SEQ ID NO: 1 CCTCATAGAGAGAGTGAAAtt SEQ ID NO:
2 GTGATTATCTCGAGCAAATtt SEQ ID NO: 3 GGAAGATGTTGTTATGTTAtt SEQ ID
NO: 4 GCTCAAGCGTGATGAAACAtt SEQ ID NO: 5 GAGTGTGAACCAAGAGATAtt SEQ
ID NO: 6 GAGTAGAAATCTTACAGAAtt SEQ ID NO: 7 ACAGAGATGCACTGAGATAtt
SEQ ID NO: 8 AGGAAATACTACAGAGTGTtt SEQ ID NO: 9
GGCAAATACTCCTGTAAATtt SEQ ID NO: 10 CATTGAAAGTAAACAGAGAtt SEQ ID
NO: 11 CCTGTAAATTTGAGTGTGAtt SEQ ID NO: 12 CAACAATACCCGAGAGTAGtt
SEQ ID NO: 13 GAATGAAACTCTCAGATCAtt SEQ ID NO: 14
AAATGAAGATCCTGTGGTAtt SEQ ID NO: 15 GTGTGAACCAAGAGATATTtt SEQ ID
NO: 16 CTACAGAGATGCACTGAGAtt SEQ ID NO: 17 ATGAAGATCCTGTGGTATTtt
SEQ ID NO: 18 GTTTATGCATCCTTAGTTAtt SEQ ID NO: 19
TCTAAATACTCTTGCAGATtt SEQ ID NO: 20 GTGAGCAAGTTCTGAAAGAtt SEQ ID
NO: 21 TGGCTAAGGAACTGGAAAAtt SEQ ID NO: 22 AAGAAGCAGTCTACAGCTAtt
SEQ ID NO: 23 GAAAGTAAACAGAGATTTGtt SEQ ID NO: 24
CTAAGGAACTGGAAAATGAtt SEQ ID NO: 25 ACAACATGCTGCAGCTGTAtt SEQ ID
NO: 26 CTGATGTATTTGAAGAAGAtt SEQ ID NO: 27 AGGCAAATCCAGACAGAACtt
SEQ ID NO: 28 GTAAACAGAGATTTGGATTtt SEQ ID NO: 29
TTGCAGATTACTTGGCTAAtt SEQ ID NO: 30 ACCCAGTACCAAAGGCAAAtt SEQ ID
NO: 31 AGGCAAATACTCCTGTAAAtt SEQ ID NO: 32 GCAAATACTCCTGTAAATTtt
SEQ ID NO: 33 CATGAAAGGCGCATCGTGAtt SEQ ID NO: 34
GGAATACACTCCAGCCTCAtt SEQ ID NO: 35 CATTTAGTGACTTGAACAAtt SEQ ID
NO: 36 TGTTGAAAGTGAAATGTCAtt SEQ ID NO: 37 CCTGTGGTATTGTGGAAATtt
SEQ ID NO: 38 GGACCAAGGCAAATCCAGAtt SEQ ID NO: 39
AGACAGAACCTTTGACTTGtt SEQ ID NO: 40 CCTTTGACTTGGTGTTGAAtt SEQ ID
NO: 41 TGCCATACCTGATTGGAATtt SEQ ID NO: 42 TGGAAGATGTTGTTATGTTtt
SEQ ID NO: 43 AGAGATGCACTGAGATACAtt SEQ ID NO: 44
TGGCTTTTGTGGAGGTAAAtt SEQ ID NO: 45 GAATCAAGTTGGACAGCACtt SEQ ID
NO: 46 ACAAATCATTGGAAGATGTtt SEQ ID NO: 47 GGACTTTGGAGACCAGGAAtt
SEQ ID NO: 48 ACTTTGGAGACCAGGAAATtt SEQ ID NO: 49
TGAAAGGGTGTCTCAGAATtt SEQ ID NO: 50
While certain of the preferred embodiments of the present invention
have been described and specifically exemplified above, it is not
intended that the invention be limited to such embodiments. Various
modifications may be made thereto without departing from the scope
and spirit of the present invention, as set forth in the following
claims.
SEQUENCE LISTINGS
1
50121DNAArtificial SequencesiRNA 1tgacagacat tgaaagtaat t
21221DNAArtificial SequencesiRNA 2cctcatagag agagtgaaat t
21321DNAArtificial SequencesiRNA 3gtgattatct cgagcaaatt t
21421DNAArtificial SequencesiRNA 4ggaagatgtt gttatgttat t
21521DNAArtificial SequencesiRNA 5gctcaagcgt gatgaaacat t
21621DNAArtificial SequencesiRNA 6gagtgtgaac caagagatat t
21721DNAArtificial SequencesiRNA 7gagtagaaat cttacagaat t
21821DNAArtificial SequencesiRNA 8acagagatgc actgagatat t
21921DNAArtificial SequencesiRNA 9aggaaatact acagagtgtt t
211021DNAArtificial SequencesiRNA 10ggcaaatact cctgtaaatt t
211121DNAArtificial SequencesiRNA 11cattgaaagt aaacagagat t
211221DNAArtificial SequencesiRNA 12cctgtaaatt tgagtgtgat t
211321DNAArtificial SequencesiRNA 13caacaatacc cgagagtagt t
211421DNAArtificial SequencesiRNA 14gaatgaaact ctcagatcat t
211521DNAArtificial SequencesiRNA 15aaatgaagat cctgtggtat t
211621DNAArtificial SequencesiRNA 16gtgtgaacca agagatattt t
211721DNAArtificial SequencesiRNA 17ctacagagat gcactgagat t
211821DNAArtificial SequencesiRNA 18atgaagatcc tgtggtattt t
211921DNAArtificial SequencesiRNA 19gtttatgcat ccttagttat t
212021DNAArtificial SequencesiRNA 20tctaaatact cttgcagatt t
212121DNAArtificial SequencesiRNA 21gtgagcaagt tctgaaagat t
212221DNAArtificial SequencesiRNA 22tggctaagga actggaaaat t
212321DNAArtificial SequencesiRNA 23aagaagcagt ctacagctat t
212421DNAArtificial SequencesiRNA 24gaaagtaaac agagatttgt t
212521DNAArtificial SequencesiRNA 25ctaaggaact ggaaaatgat t
212621DNAArtificial SequencesiRNA 26acaacatgct gcagctgtat t
212721DNAArtificial SequencesiRNA 27ctgatgtatt tgaagaagat t
212821DNAArtificial SequencesiRNA 28aggcaaatcc agacagaact t
212921DNAArtificial SequencesiRNA 29gtaaacagag atttggattt t
213021DNAArtificial SequencesiRNA 30ttgcagatta cttggctaat t
213121DNAArtificial SequencesiRNA 31acccagtacc aaaggcaaat t
213221DNAArtificial SequencesiRNA 32aggcaaatac tcctgtaaat t
213321DNAArtificial SequencesiRNA 33gcaaatactc ctgtaaattt t
213421DNAArtificial SequencesiRNA 34catgaaaggc gcatcgtgat t
213521DNAArtificial SequencesiRNA 35ggaatacact ccagcctcat t
213621DNAArtificial SequencesiRNA 36catttagtga cttgaacaat t
213721DNAArtificial SequencesiRNA 37tgttgaaagt gaaatgtcat t
213821DNAArtificial SequencesiRNA 38cctgtggtat tgtggaaatt t
213921DNAArtificial SequencesiRNA 39ggaccaaggc aaatccagat t
214021DNAArtificial SequencesiRNA 40agacagaacc tttgacttgt t
214121DNAArtificial SequencesiRNA 41cctttgactt ggtgttgaat t
214221DNAArtificial SequencesiRNA 42tgccatacct gattggaatt t
214321DNAArtificial SequencesiRNA 43tggaagatgt tgttatgttt t
214421DNAArtificial SequencesiRNA 44agagatgcac tgagatacat t
214521DNAArtificial SequencesiRNA 45tggcttttgt ggaggtaaat t
214621DNAArtificial SequencesiRNA 46gaatcaagtt ggacagcact t
214721DNAArtificial SequencesiRNA 47acaaatcatt ggaagatgtt t
214821DNAArtificial SequencesiRNA 48ggactttgga gaccaggaat t
214921DNAArtificial SequencesiRNA 49actttggaga ccaggaaatt t
215021DNAArtificial SequencesiRNA 50tgaaagggtg tctcagaatt t 21
* * * * *
References